NZ618570B2 - Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides - Google Patents
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Download PDFInfo
- Publication number
- NZ618570B2 NZ618570B2 NZ618570A NZ61857012A NZ618570B2 NZ 618570 B2 NZ618570 B2 NZ 618570B2 NZ 618570 A NZ618570 A NZ 618570A NZ 61857012 A NZ61857012 A NZ 61857012A NZ 618570 B2 NZ618570 B2 NZ 618570B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- acid
- linear
- branched
- aryl
- units
- Prior art date
Links
- -1 3-hydroxypyridine-2-carbonyl Chemical group 0.000 title claims abstract description 247
- 150000002148 esters Chemical class 0.000 title claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract description 12
- 150000001408 amides Chemical class 0.000 title description 11
- 238000004519 manufacturing process Methods 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000001072 heteroaryl group Chemical group 0.000 claims description 49
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004429 atoms Chemical group 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 16
- 150000001768 cations Chemical class 0.000 claims description 15
- 125000005842 heteroatoms Chemical group 0.000 claims description 15
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 claims description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 150000002829 nitrogen Chemical group 0.000 claims description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- CZGLBWZXGIAIBU-UHFFFAOYSA-N 4-azaniumyl-3-methylbutanoate Chemical compound NCC(C)CC(O)=O CZGLBWZXGIAIBU-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- LBWJTKOVBMVJJX-UHFFFAOYSA-N (2-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC=C1B(O)O LBWJTKOVBMVJJX-UHFFFAOYSA-N 0.000 claims 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 claims 2
- NPLZNDDFVCGRAG-UHFFFAOYSA-N (2-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C#N NPLZNDDFVCGRAG-UHFFFAOYSA-N 0.000 claims 2
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 claims 2
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 claims 2
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 claims 2
- SFUIGUOONHIVLG-UHFFFAOYSA-N (2-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1[N+]([O-])=O SFUIGUOONHIVLG-UHFFFAOYSA-N 0.000 claims 2
- WDGWHKRJEBENCE-UHFFFAOYSA-N (3-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC(B(O)O)=C1 WDGWHKRJEBENCE-UHFFFAOYSA-N 0.000 claims 2
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 claims 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 claims 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 claims 2
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 claims 2
- GNRHNKBJNUVWFZ-UHFFFAOYSA-N (4-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=C(B(O)O)C=C1 GNRHNKBJNUVWFZ-UHFFFAOYSA-N 0.000 claims 2
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 claims 2
- CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 claims 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 claims 2
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 claims 2
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-Aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims 2
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-Nitrophenylboronic Acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 claims 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 229960000310 ISOLEUCINE Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- RGQWCMSURYEQHR-UHFFFAOYSA-N [2-(cyclopropanecarbonylamino)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1NC(=O)C1CC1 RGQWCMSURYEQHR-UHFFFAOYSA-N 0.000 claims 2
- HCVMQMSUJGYKOB-UHFFFAOYSA-N [2-(pyrrolidine-1-carbonyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(=O)N1CCCC1 HCVMQMSUJGYKOB-UHFFFAOYSA-N 0.000 claims 2
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 claims 2
- DGXXULNJZFCUEP-UHFFFAOYSA-N [3-(cyclopropanecarbonylamino)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(NC(=O)C2CC2)=C1 DGXXULNJZFCUEP-UHFFFAOYSA-N 0.000 claims 2
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 claims 2
- UVEPVVVRJXGARC-UHFFFAOYSA-N [4-(cyclopropanecarbonylamino)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1NC(=O)C1CC1 UVEPVVVRJXGARC-UHFFFAOYSA-N 0.000 claims 2
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 claims 2
- 229960003692 aminobutyric acid Drugs 0.000 claims 2
- NSFJAFZHYOAMHL-UHFFFAOYSA-N (4-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=C([N+]([O-])=O)C=C1 NSFJAFZHYOAMHL-UHFFFAOYSA-N 0.000 claims 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- SXTMJRKRWYTPLI-UHFFFAOYSA-N [3-(pyrrolidine-1-carbonyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(=O)N2CCCC2)=C1 SXTMJRKRWYTPLI-UHFFFAOYSA-N 0.000 claims 1
- VKPBESPVHGDDJS-UHFFFAOYSA-N [4-(pyrrolidine-1-carbonyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C(=O)N1CCCC1 VKPBESPVHGDDJS-UHFFFAOYSA-N 0.000 claims 1
- 239000003377 acid catalyst Substances 0.000 claims 1
- 230000003301 hydrolyzing Effects 0.000 claims 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract description 24
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 21
- 239000003112 inhibitor Substances 0.000 abstract description 17
- 239000000651 prodrug Substances 0.000 abstract description 17
- 229940002612 prodrugs Drugs 0.000 abstract description 17
- IZQMRNMMPSNPJM-UHFFFAOYSA-N 2-[(3-hydroxypyridine-2-carbonyl)amino]acetic acid Chemical class OC(=O)CNC(=O)C1=NC=CC=C1O IZQMRNMMPSNPJM-UHFFFAOYSA-N 0.000 abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 4
- GFZDAVUZFZZKJI-UHFFFAOYSA-N N-(2-amino-2-oxoethyl)-3-hydroxypyridine-2-carboxamide Chemical class NC(=O)CNC(=O)C1=NC=CC=C1O GFZDAVUZFZZKJI-UHFFFAOYSA-N 0.000 abstract description 3
- 235000011054 acetic acid Nutrition 0.000 abstract description 2
- 230000000670 limiting Effects 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 125000004432 carbon atoms Chemical group C* 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 125000002837 carbocyclic group Chemical group 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000008079 hexane Substances 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- YTLGQWBFHNKITM-UHFFFAOYSA-N methyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino]acetate Chemical compound C1=C(O)C(NCC(=O)OC)=NC=C1C1=CC=CC(Cl)=C1 YTLGQWBFHNKITM-UHFFFAOYSA-N 0.000 description 9
- DYUOYBIHGUNMQN-UHFFFAOYSA-N 3-chloro-5-(3-chlorophenyl)pyridine-2-carbonitrile Chemical compound ClC1=CC=CC(C=2C=C(Cl)C(C#N)=NC=2)=C1 DYUOYBIHGUNMQN-UHFFFAOYSA-N 0.000 description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- NDOKHNXIIYLZPY-UHFFFAOYSA-N 2-[[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino]acetic acid Chemical compound C1=C(O)C(NCC(=O)O)=NC=C1C1=CC=CC(Cl)=C1 NDOKHNXIIYLZPY-UHFFFAOYSA-N 0.000 description 7
- KMZAXKDGIXGPOF-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid Chemical compound C1=C(O)C(C(=O)O)=NC=C1C1=CC=CC(Cl)=C1 KMZAXKDGIXGPOF-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- LQXLPTXROAPSNP-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-methoxypyridine-2-carbonitrile Chemical compound N1=C(C#N)C(OC)=CC(C=2C=C(Cl)C=CC=2)=C1 LQXLPTXROAPSNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000012265 solid product Substances 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000012970 cakes Nutrition 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- DITHIFQMPPCBCU-UHFFFAOYSA-N propa-1,2-diene Chemical group [CH]=C=C DITHIFQMPPCBCU-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- ATUOLSDAAPMVJJ-UHFFFAOYSA-N 3,5-dichloropyridine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C(Cl)=C1 ATUOLSDAAPMVJJ-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- RMRFFCXPLWYOOY-UHFFFAOYSA-N Allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N-diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 3
- 102000014961 Protein Precursors Human genes 0.000 description 3
- 108010078762 Protein Precursors Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N Ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229960003194 Meglumine Drugs 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N Nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical group [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N carbon bisulphide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 125000004360 trifluorophenyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RUYDTNPMBFSJGP-UHFFFAOYSA-N 1,3,5-trimethyl-4,6-dimethylidenecyclohexene Chemical group CC1C=C(C)C(=C)C(C)C1=C RUYDTNPMBFSJGP-UHFFFAOYSA-N 0.000 description 1
- ZYGCUMLAHDLONP-UHFFFAOYSA-N 1-(2-oxopiperidin-3-yl)piperidin-2-one Chemical compound O=C1NCCCC1N1C(=O)CCCC1 ZYGCUMLAHDLONP-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-Trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- GXDHCNNESPLIKD-UHFFFAOYSA-N 2-Methylhexane Chemical compound CCCCC(C)C GXDHCNNESPLIKD-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- KMOSYGOJLQCKJL-UHFFFAOYSA-N 2-chloro-1,4-dimethoxy-2H-1,3,5-triazine Chemical compound CON1C=NC(OC)=NC1Cl KMOSYGOJLQCKJL-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- SAKUQCVNSVHPIW-UHFFFAOYSA-N 3,5-dibromopyridine-2-carbonitrile Chemical compound BrC1=CN=C(C#N)C(Br)=C1 SAKUQCVNSVHPIW-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N 3-Pentanone Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- AAGYWTCZOUXEDH-UHFFFAOYSA-N 3-bromo-5-chloropyridine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C(Br)=C1 AAGYWTCZOUXEDH-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- YDPLFBIGFQFIDB-UHFFFAOYSA-N 3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC=CN=C1C#N YDPLFBIGFQFIDB-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- SIYPZKHSXDFDRA-UHFFFAOYSA-N 5-bromo-3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC(Br)=CN=C1C#N SIYPZKHSXDFDRA-UHFFFAOYSA-N 0.000 description 1
- BJUPTJXRJDXLHF-UHFFFAOYSA-N 6,7-dihydro-5H-cyclopenta[d]pyrimidine Chemical compound N1=CN=C2CCCC2=C1 BJUPTJXRJDXLHF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 1
- YEDIXGHCQSQRBD-UHFFFAOYSA-M C1=C(O)C([N-]CC(=O)N)=NC=C1C1=CC=CC(Cl)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N)=NC=C1C1=CC=CC(Cl)=C1 YEDIXGHCQSQRBD-UHFFFAOYSA-M 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O CC[NH+](CC)CC Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N Hexamethylphosphoramide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N M-Xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- 229940017219 METHYL PROPIONATE Drugs 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N N,N-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-O NCC[OH2+] Chemical compound NCC[OH2+] HZAXFHJVJLSVMW-UHFFFAOYSA-O 0.000 description 1
- UJTMLNARSPORHR-UHFFFAOYSA-N OC2H5 Chemical compound C=C=[O+] UJTMLNARSPORHR-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N Tris-Hydroxymethyl-Methyl-Ammonium Chemical compound OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- ZHHGTMQHUWDEJF-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 ZHHGTMQHUWDEJF-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-O bis(2-hydroxyethyl)azanium Chemical compound OCC[NH2+]CCO ZBCBWPMODOFKDW-UHFFFAOYSA-O 0.000 description 1
- CYKRMWNZYOIJCH-UHFFFAOYSA-N bromo(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(Br)N1CCCC1 CYKRMWNZYOIJCH-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 1
- GNVRJGIVDSQCOP-UHFFFAOYSA-O diethyl(methyl)azanium Chemical compound CC[NH+](C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-O 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylazanium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-O dimethylaminium Chemical compound C[NH2+]C ROSDSFDQCJNGOL-UHFFFAOYSA-O 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-O ethyl(dimethyl)azanium Chemical compound CC[NH+](C)C DAZXVJBJRMWXJP-UHFFFAOYSA-O 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O methylammonium Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005646 oximino group Chemical group 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- NBEOBNPETXOCKI-UHFFFAOYSA-N propan-2-ylchloranuidyl formate Chemical compound CC(C)[Cl-]OC=O NBEOBNPETXOCKI-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-O trimethylammonium Chemical compound C[NH+](C)C GETQZCLCWQTVFV-UHFFFAOYSA-O 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Abstract
Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino} acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino} acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired. )-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino} acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.
Description
PROCESS FOR PREPARING
[(3-HYDROXYPYRIDINECARBONYL)AMINO]ALKANOIC ACIDS,
ESTERS AND AMIDES
PRIORITY
This Application claims priority from US. Provisional Application Serial No.
61/493,536, filed June 6, 2011, the entirety of which is included herein by reference.
FIELD
Disclosed are processes for preparing droxypyridine—2-carbonyl)amino]-
alkanoic acids, derivatives, inter alia, 5—aryl substituted and 5— aryl substituted [(3—
hydroxypyridine—2-carbonyl]amino}acetic acids. Further sed are methods for making
prodrugs of [(3 —hydroxypyridinecarbonyl)-amino]acetic acids, for example, [(3-
hydroxypyridinecarbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2—
carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl
hydroxylase tors or for treating conditions wherein prolyl hydroxylase inhibition is
desired.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts an outline of one embodiment for preparing the disclosed prolyl
hydroxylase inhibitors.
Figure 2 depicts an outline of one ment for preparing the disclosed prolyl
hydroxylase inhibitor ester prodrugs.
Figure 3 depicts an outline of one embodiment for preparing the disclosed prolyl
hydroxylase inhibitor amide gs.
DETAILED SURE
The materials, nds, itions, articles, and methods described herein
may be understood more readily by reference to the following detailed description of
specific aspects of the disclosed subject matter and the Examples included therein.
Before the present materials, compounds, compositions, articles, devices, and
methods are disclosed and described, it is to be understood that the aspects described below
are not limited to specific synthetic methods or specific reagents, as such may, of course,
vary. It is also to be understood that the terminology used herein is for the purpose of
describing particular aspects only and is not intended to be limiting.
Also, throughout this specification, various ations are referenced. The
sures of these publications in their entireties are hereby orated by reference into
this application in order to more fully describe the state of the art to which the disclosed
matter pertains. The nces sed are also individually and specifically incorporated
by reference herein for the material contained in them that is discussed in the sentence in
which the nce is relied upon.
General Definitions
In this specification and in the claims that follow, reference will be made to a
number of terms, which shall be defined to have the following meanings:
All percentages, ratios and proportions herein are by weight, unless otherwise
ied. All temperatures are in degrees Celsius (0C) unless ise specified.
By "pharmaceutically acceptable" is meant a material that is not biologically or
otherwise undesirable, i.e., the material can be administered to an individual along with the
relevant active compound without causing clinically unacceptable biological s or
interacting in a deleterious manner with any of the other components of the pharmaceutical
composition in which it is contained.
A weight percent of a component, unless specifically stated to the contrary, is based
on the total weight of the formulation or composition in which the component is included.
“Admixture” or “blend” is generally used herein means a physical ation of
two or more different components.
Throughout the description and claims of this specification the word “comprise” and
other forms of the word, such as “comprising” and “comprises,” means including but not
d to, and is not intended to exclude, for example, other additives, components,
integers, or steps.
As used in the description and the appended claims, the singular forms “a,” “an,”
and “the” include plural referents unless the context clearly es otherwise. Thus, for
example, reference to “[(3 -hydroxypyridinecarbonyl)amino]alkanoic acid” es
mixtures of two or more such [(3 -hydroxypyridinecarbonyl)amino]alkanoic acids,
reference to “the compound” includes mixtures of two or more such compounds, which can
include mixtures of l isomers (racemic mixtures), and the like.
“Optional” or “optionally” means that the subsequently bed event or
circumstance can or cannot occur, and that the description includes instances where the
event or circumstance occurs and instances where it does not.
Ranges can be expressed herein as from “about” one particular value, and/or to
“about” another particular value. When such a range is expressed, another aspect includes
from the one particular value and/or to the other particular value. Similarly, when values
are expressed as approximations, by use of the antecedent “about,” it will be tood that
the particular value forms another aspect. It will be further understood that the endpoints of
each of the ranges are significant both in relation to the other endpoint, and independently
of the other endpoint. It is also understood that there are a number of values disclosed
herein, and that each value is also herein disclosed as “about” that particular value in
addition to the value . For example, if the value “10” is disclosed, then “about 10” is
also disclosed. It is also understood that when a value is disclosed, then “less than or equal
to” the value, “greater than or equal to the value,” and possible ranges between values are
also disclosed, as riately understood by the skilled artisan. For example, if the value
“10” is disclosed, then “less than or equal to 10” as well as er than or equal to 10” is
also disclosed. It is also understood that throughout the application data are provided in a
number of different formats and that this data represent endpoints and starting points and
ranges for any combination of the data points. For example, if a particular data point “10”
and a particular data point “15” are disclosed, it is understood that greater than, greater than
or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed
as well as between 10 and 15. It is also understood that each unit between two particular
units are also sed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are
also disclosed.
The ing chemical hierarchy is used throughout the specification to describe
and enable the scope of the present disclosure and to particularly point out and distinctly
claim the units which comprise the compounds of the present disclosure, however, unless
ise ically defined, the terms used herein are the same as those of the artisan of
ry skill. The term “hydrocarbyl” stands for any carbon atom-based unit (organic
molecule), said units optionally ning one or more organic functional group, including
nic atom comprising salts, inter alia, carboxylate salts, quaternary ammonium salts.
Within the broad meaning of the term “hydrocarbyl” are the s “acyclic hydrocarbyl”
and “cyclic hydrocarbyl” which terms are used to divide hydrocarbyl units into cyclic and
non—cyclic classes.
As it relates to the following definitions, “cyclic hydrocarbyl” units can comprise
only carbon atoms in the ring (i.e., carbocyclic and aryl rings) or these units can comprise
one or more heteroatoms in the ring (i.e., heterocyclic and heteroaryl rings). For
“carbocyclic” rings the lowest number of carbon atoms in a ring is 3 carbon atoms;
cyclopropyl. For “aryl” rings the lowest number of carbon atoms in a ring are 6 carbon
atoms; phenyl. For “heterocyclic” rings the lowest number of carbon atoms in a ring is l
carbon atom; diazirinyl, a C1 heterocyclic ring. Ethylene oxide comprises 2 carbon atoms
and is a C2 heterocyclic ring. For “heteroaryl” rings the lowest number of carbon atoms in a
ring is 1 carbon atom; l,2,3,4-tetrazolyl, a C1 heteroaryl ring. The terms “heterocycle” and
“heterocyclic ring” can also include “heteroaryl rings.” The ing is a non-limiting
description of the units encompassed by the terms “acyclic arbyl” and “cyclic
hydrocarbyl” as used herein.
A. Substituted and unsubstituted c hydrocarbyl:
For the purposes of the present disclosure the term “substituted and unsubstituted
acyclic hydrocarbyl” encompasses 3 categories of units:
1) linear or branched alkyl, non-limiting examples of which e, methyl (C1), ethyl
(C2), yl (C3), opyl (C3), n—butyl (C4), sec—butyl (C4), iso—butyl (C4), tert—
butyl (C4), and the like; substituted linear or branched alkyl, non-limiting examples
of which includes, hydroxymethyl (C1), chloromethyl (C1), trifluoromethyl (C1),
aminomethyl (C1), l-chloroethyl (C2), 2-hydroxyethyl (C2), fluoroethyl (C2),
3—carboxypropyl (C3), and the like.
2) linear or branched alkenyl, non-limiting examples of which include, ethenyl (C2), 3—
yl (C3), l-propenyl (also 2-methylethenyl) (C3), penyl (also 2—
methylethenyl) (C3), butenyl (C4), and the like; substituted linear or branched
alkenyl, non-limiting examples of which include, 2-chloroethenyl (also 2—
chlorovinyl) (C2), 4-hydroxybuten-l-yl (C4), 7-hydroxymethylocten-2—yl (C9),
7—hydroxymethyloct-3,5-dienyl (C9), and the like.
3) linear or branched alkynyl, non-limiting es of which include, ethynyl (C2),
prop—2—ynyl (also propargyl) (C3), -l-yl (C3), and 2—methyl-hexyn-l-yl
(C7); substituted linear or branched alkynyl, non-limiting examples of which
include, oxymethylhexynyl (C7), 6-hydroxymethylhept-3 -ynyl
(Cg), 5—hydroxy—5—ethylhept-3 -ynyl (C9), and the like.
B. Substituted and unsubstituted cyclic hydrocarbyl:
For the purposes of the present disclosure the term “substituted and unsubstituted
cyclic hydrocarbyl” encompasses 5 categories of units:
2012/040833
l) The term “carbocyclic” is defined herein as “encompassing rings comprising from 3
to 20 carbon atoms, in one embodiment from 3 to 10 carbon atoms, in another
embodiment from 3 to 7 carbon atoms, in a still further embodiment 5 or 6 carbon
atoms, wherein the atoms which comprise said rings are limited to carbon atoms,
and further each ring can be independently substituted with one or more moieties
capable of replacing one or more hydrogen atoms.” The following are non-limiting
es of “substituted and unsubstituted carbocyclic rings” which encompass the
following ries of units:
i) carbocyclic rings having a single substituted or unsubstituted hydrocarbon
ring, non-limiting examples of which e, cyclopropyl (C3), 2—methyl—
cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), 2,3—dihydroxycyclobutyl
(C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclopentadienyl
(C5), cyclohexyl (C6), cyclohexenyl (C6), cycloheptyl (C7), cyclooctanyl (Cg), 2,5—
dimethylcyclopentyl (C5), 3,5—dichlorocyclohexyl (C6), 4—hydroxycyclohexyl (C6),
and 3 ,3 ,5 thylcyclohex- l -yl (C6).
ii) carbocyclic rings having two or more substituted or unsubstituted fused
arbon rings, non-limiting examples of which include, octahydropentalenyl
(Cg), octahydro- enyl (C9), 3a,4,5,6,7,7a-hexahydro-3H—indenyl (C9),
decahydroazulenyl (C10).
iii) carbocyclic rings which are substituted or unsubstituted bicyclic hydrocarbon
rings, non-limiting examples of which include, o-[2. l. l]hexanyl,
bicyclo[2.2. l]heptanyl, bicyclo[3. l. l]heptanyl, l,3 -dimethyl[2.2. l ]heptan-2—yl,
bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
2) The term “aryl” is defined herein as “units encompassing at least one phenyl or
naphthyl ring and wherein there are no heteroaryl or heterocyclic rings fused to the
phenyl or naphthyl ring and further each ring can be independently tuted with
one or more moieties capable of replacing one or more hydrogen atoms.” The
following are non-limiting examples of “substituted and unsubstituted aryl rings”
which encompass the ing categories of units:
i) C6 or C10 substituted or unsubstituted aryl rings; phenyl and naphthyl rings
whether substituted or unsubstituted, non-limiting es of which include,
phenyl (C6), naphthylen-l-yl (C10), naphthylenyl (C10), 4-fluorophenyl (C6), 2-
hydroxyphenyl (C6), 3-methylphenyl (C6), 2-aminofluorophenyl (C6), 2-(N,N—
diethylamino)phenyl (C6), 2—cyanophenyl (C6), 2,6—di—tert—butylphenyl (C6), 3—
methoxyphenyl (C6), 8-hydroxynaphthylen-2—yl (C10), 4,5-dimethoxynaphthylen-l-
yl (C10), and 6-cyano-naphthylen-l-yl (C10).
ii) C6 or C10 aryl rings fused with l or 2 saturated rings to afford C8-C20 ring
systems, non-limiting examples of which include, o[4.2.0]octa-l,3,5-trienyl
(Cg), and indanyl (C9).
3) The terms “heterocyclic” and/or “heterocycle” are defined herein as “units
comprising one or more rings having from 3 to 20 atoms wherein at least one atom
in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (0), or sulfur
(S), or mixtures of N, O, and S, and wherein further the ring which contains the
heteroatom is also not an aromatic ring.” The following are non-limiting examples
of “substituted and unsubstituted heterocyclic rings” which ass the following
categories of units:
i) heterocyclic units haVing a single ring containing one or more heteroatoms,
non-limiting es of which include, diazirinyl (C1), inyl (C2), urazolyl
(C2), azetidinyl (C3), pyrazolidinyl (C3), imidazolidinyl (C3), oxazolidinyl (C3),
isoxazolinyl (C3), thiazolidinyl (C3), isothiazolinyl (C3), azolidinonyl (C3),
oxazolidinonyl (C3), hydantoinyl (C3), tetrahydrofuranyl (C4), idinyl (C4),
morpholinyl (C4), zinyl (C4), dinyl (C4), dihydropyranyl (C5),
tetrahydropyranyl (C5), piperidinonyl (valerolactam) (C5), 2,3,4,5-tetrahydro-1H-
azepinyl (C6), 2,3-dihydro-lH—indole (Cg), and l,2,3,4-tetrahydroquinoline (C9).
ii) heterocyclic units haVing 2 or more rings one of which is a heterocyclic ring,
non-limiting examples of which e hexahydro- 1H-pyrrolizinyl (C7),
3 a,4,5,6,7,7a-hexahydro- lH—benzo[d]imidazolyl (C7), 3a,4,5,6,7,7a—hexahydro- 1H-
indolyl (Cg), l,2,3,4-tetrahydroquinolinyl (C9), and decahydro-lH—
cycloocta[b]pyrrolyl (C10).
4) The term “heteroaryl” is defined herein as “encompassing one or more rings
comprising from 5 to 20 atoms wherein at least one atom in at least one ring is a
heteroatom chosen from nitrogen (N), oxygen (0), or sulfur (S), or mixtures of N,
O, and S, and wherein further at least one of the rings which comprises a atom
is an aromatic ring.” Heteroaryl rings can comprise from 1 to 19 carbon atoms, in
another embodiment heteroaryl rings can comprise from 1 to 9 carbon atoms. The
following are non—limiting examples of “substituted and unsubstituted cyclic
rings” which ass the following ries of units:
i) aryl rings containing a single ring, non-limiting examples of which
include, l,2,3,4-tetrazolyl (C1), [1,2,3]triazolyl (C2), [1,2,4]triazolyl (C2), triazinyl
(C3), thiazolyl (C3), lH—imidazolyl (C3), yl (C3), isoxazolyl (C3), isothiazolyl
(C3), furanyl (C4), thiophenyl (C4), pyrimidinyl (C4), 2-phenylpyrimidinyl (C4),
pyridinyl (C5), 3-methylpyridinyl (C5), and 4-dimethylaminopyridinyl (C5)
ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl
ring, non-limiting examples of which e: 7H—purinyl (C5), 9H—purinyl (C5), 6—
amino-9H—purinyl (C5), 5H—pyrrolo[3,2—d]pyrimidinyl (C6), 7H—pyrrolo[2,3-
d]pyrimidinyl (C6), pyrido[2,3-d]pyrimidinyl (C7), ylbenzo[d]thiazolyl (C7),
lH—indolyl (Cg), 4,5,6,7-tetrahydro-l-H—indolyl (Cg), quinoxalinyl (Cg), 5-
uinoxalinyl (Cg), quinazolinyl (Cg), quinolinyl (C9), 8-hydroxy-quinolinyl
(C9), and isoquinolinyl (C9).
5) C1—C6 tethered cyclic hydrocarbyl units (whether carbocyclic units, C6 or C10 aryl
units, heterocyclic units, or heteroaryl units) which connected to another moiety,
unit, or core of the molecule by way of a C1-C6 alkylene unit. Non-limiting
examples of tethered cyclic hydrocarbyl units include benzyl C1-(C6) haVing the
formula:
m —%\/
wherein Ra is optionally one or more independently chosen substitutions for
hydrogen. Further examples include other aryl units, inter alia, (2—
hydroxyphenyl)hexyl C6-(C6); naphthalen-2—ylmethyl C1-(C10), 4-fluorobenzyl C1-
(C6), 2—(3 -hydroxyphenyl)ethyl C2-(C6), as well as substituted and unsubstituted C3—
C10 alkylenecarbocyclic units, for example, cyclopropylmethyl C1-(C3),
cyclopentylethyl ), cyclohexylmethyl C1-(C6);. Included within this category
are substituted and unsubstituted C1-C10 alkylene-heteroaryl units, for example a 2—
picolyl C1-(C6) unit haVing the formula:
—CH,QRa
wherein Ra is the same as defined above. In addition, C1—C12 tethered cyclic
hydrocarbyl units e C1-C10 alkyleneheterocyclic units and alkylene-heteroaryl
units, miting examples of which include, aziridinylmethyl Cl-(Cz) and —
2—ylmethyl Cl—(C3).
For the purposes of the present disclosure carbocyclic rings are from C3 to C20; aryl
rings are C6 or C10; heterocyclic rings are from C1 to C9; and heteroaryl rings are from C1 to
For the purposes of the present disclosure, and to provide consistency in defining the
present disclosure, fused ring units, as well as spirocyclic rings, bicyclic rings and the like,
which comprise a single heteroatom will be characterized and referred to herein as being
encompassed by the cyclic family corresponding to the heteroatom containing ring,
although the artisan may have alternative characterizations. For example, l,2,3,4-
tetrahydroquinoline having the a:
is, for the purposes of the present disclosure, defined as a heterocyclic unit. 6,7—Dihydro—
5H—cyclopentapyrimidine having the formula:
Nfi?MN/
is, for the purposes of the present disclosure, is defined as a heteroaryl unit. When a fused
ring unit contains heteroatoms in both a non-aromatic ring (heterocyclic ring) and an aryl
ring (heteroaryl ring), the aryl ring will predominate and determine the type of ry to
which the ring is ed herein for the purposes of describing the invention. For example,
l,2,3,4-tetrahydro-[1,8]naphthpyridine having the formula:
N E
is, for the purposes of the t sure, is defined as a aryl unit.
The term “substituted” is used throughout the specification. The term “substituted” is
applied to the units described herein as “substituted unit or moiety is a hydrocarbyl unit or
, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a
substituent or several substituents as defined herein below.” The units, when substituting
for hydrogen atoms are capable of replacing one hydrogen atom, two hydrogen atoms, or
three en atoms of a hydrocarbyl moiety at a time. In addition, these substituents can
replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety,
or unit. For example, a substituted unit that requires a single hydrogen atom replacement
includes halogen, hydroxyl, and the like. A two en atom replacement includes
carbonyl, oximino, and the like. A two hydrogen atom replacement from nt carbon
atoms includes epoxy, and the like. Three hydrogen replacement includes cyano, and the
like. The term substituted is used throughout the present specification to indicate that a
hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain; can have one or more of the
hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any
number of the hydrogen atoms may be ed. For example, 4-hydroxyphenyl is a
“substituted ic carbocyclic ring (aryl ring)”, (N,N—dimethylamino)octanyl is a “
tuted Cg linear alkyl unit, 3-guanidinopropyl is a “substituted C3 linear alkyl unit,” and
2-carboxypyridinyl is a “substituted heteroaryl unit.”
The following are non-limiting examples of units which can tute for hydrogen
atoms on a carbocyclic, aryl, heterocyclic, or heteroaryl unit:
i) substituted or unsubstituted C1—C12 linear, C3—C12 branched, or C3—C12 cyclic
alkyl, alkenyl, and l; methyl (C1), ethyl (C2), ethenyl (C2), ethynyl
(C2), n—propyl (C3), iso—propyl (C3), cyclopropyl (C3), enyl (C3), 1—
propenyl (also 2—methylethenyl) (C3), isopropenyl (also ylethenyl)
(C3), prop-2—ynyl (also propargyl) (C3), propyn—l—yl (C3), n—butyl (C4), sec—
butyl (C4), iso—butyl (C4), tert—butyl (C4), cyclobutyl (C4), buten—4—yl (C4),
entyl (C5), cyclohexyl (C6);
ii) substituted or unsubstituted C6 or C10 aryl; for e, phenyl, naphthyl
(also referred to herein as naphthylen-l-yl (C10) or naphthylenyl (C10));
iii) substituted or unsubstituted C7 or C11 alkylenearyl; for example, benzyl, 2-
phenylethyl, naphthylenylmethyl;
iV) substituted or unsubstituted C1—C9 heterocyclic rings; as described herein
below;
V) substituted or unsubstituted C1—C9 heteroaryl rings; as described herein
below;
Vi) —(CR1023R102b)aOR101; for example, —OH, , —OCH3, —CHZOCH3,
—OCH2CH3, —CH20CH2CH3, —OCH2CH2CH3, and —CH20CH2CH2CH3;
vii) —(CR1023R102b)aC(O)R101; for example, —COCH3, —CH2COCH3,
—COCH2CH3, —CH2COCH2CH3, —COCH2CH2CH3, and
—CH2COCH2CH2CH3;
viii) —(CR102aR102b)aC(O)OR101; for example, —C02CH3, —CH2COZCH3,
—COZCH2CH3, —CH2COZCH2CH3, —COZCH2CH2CH3, and
—CH2COZCH2CH2CH3;
ix) zaRlozb)aC(O)N(R101)2; for example, —CONH2, —CH2CONH2,
H3, —CH2CONHCH3, —CON(CH3)2, and N(CH3)2;
x) —(CR1023R102b)aN(R101) C(0)R101, for example, —NHCOCH3,
—CH2NHCOCH3, —NHCOCH2CH3, and COCH2CH3;
xi) —(CR102aR102b)aN(R101) C(O)2R101; for example, —NHCOZCH3,
—CH2NHCOZCH3, —NHCOZCH2CH3, and —CH2NHCOZCH2CH3;
xii) 2aR102b)aN(R101)2, for example, —NH2, —CH2NH2, —NHCH3,
—CH2NHCH3, —N(CH3)2, and —CH2N(CH3)2;
xiii) halogen; —F, —Cl, —Br, and —I;
xiv) —(CR102aR102b)aCN;
xv) —(CR102aR102b)aNOZ;
xvi) —(CHj,Xka)aCHJ-Xk; wherein X is halogen, the index j is an integer from 0 to
2,j + k = 3; the indexj’ is an integer from 0 to 2, j’ + k’ = 2; for example,
—CH2F; —CHF2; —CH2CH2F; —CH2CHF2; —CF3; —CC13; 01' —CBI‘3;
xvii) —(CR102aR102b),SR101, —SH, —CHZSH, —SCH3, —CHZSCH3, —SC6H5, and
—CstC6H5;
xviii) —(CR102aR102b)aSOzR101; for example, —SOzH, —CHZSOZH, —SOZCH3,
—CHZSOZCH3, —SOZC6H5, and ZC6H5; and
xix) —(CR1023R102b)aSO3R101; for e, —so3H, 3H, —SO3CH3,
—CstO3CH3, —SO3C6H5, and —CstO3C6H5;
wherein each R101 is independently hydrogen, substituted or unsubstituted C1—C6 linear, C3—
C6 branched, or C3—C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or aryl; or two R101
units can be taken together to form a ring comprising 3-7 atoms; R102a and R10% are each
independently hydrogen or C1—C4 linear or C3—C4 branched alkyl; the index “a” is from 0 to
The substitutions for hydrogen defined herein above, for example, substituted C1—C12
linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl, substituted C6 or C10
2012/040833
aryl, substituted C7 or C11 alkylenearyl, substituted C1—C9 heterocyclic rings, substituted C1—
C9 heteroaryl rings, and R101, can be ally substituted by one or more of the following
substitutions for hydrogen:
0 C1—C12 linear, C3—C12 ed, or C3-C12 cyclic alkyl, alkenyl, and alkynyl;
methyl (C1), ethyl (C2), ethenyl (C2), ethynyl (C2), n—propyl (C3), iso—propyl
(C3), cyclopropyl (C3), 3—propenyl (C3), l—propenyl (also 2—methylethenyl)
(C3), isopropenyl (also ylethen—2—yl) (C3), prop—2—ynyl (also
propargyl) (C3), propyn-l-yl (C3), n—butyl (C4), sec—butyl (C4), iso—butyl (C4),
tert—butyl (C4), cyclobutyl (C4), buten—4—yl (C4), cyclopentyl (C5), cyclohexyl
(C6);
ii) C6 or C10 aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen- l -yl (C10) or naphthylenyl ;
iii) C7 or C11 alkylenearyl; for example, , 2—phenylethyl, naphthylen-2—
ylmethyl;
iV) C1—C9 heterocyclic rings; as described herein below;
C1-C9 heteroaryl rings; as described herein below;
Vi) —(CR2023R202b)bOR201; for example, —OH, —CH20H, —OCH3, —CHZOCH3,
—OCH2CH3, —CH20CH2CH3, —OCH2CH2CH3, and —CH20CH2CH2CH3;
Vii) —(CR202aR202b)bC(O)R201; for example, —COCH3, —CH2COCH3,
—COCH2CH3, CH2CH3, —COCH2CH2CH3, and
—CH2COCH2CH2CH3;
viii) —(CR202aR202b)bC(O)OR201; for example, —COzCH3, —CH2C02CH3,
—COzCH2CH3, —CH2COZCH2CH3, —COzCH2CH2CH3, and
—CH2COZCH2CH2CH3;
ix) —(CR2023R202b)bC(O)N(R201)2; for example, —CONH2, —CH2CONH2,
H3, —CH2CONHCH3, —CON(CH3)2, and —CH2CON(CH3)2;
—(CR202aR202b)bN(R201) C(O)R201; for example, —NHCOCH3,
—CH2NHCOCH3, —NHCOCH2CH3, and —CH2NHCOCH2CH3;
xi) 23R202b)bN(R201) C(O)2R201; for example, —NHC02CH3,
—CH2NHC02CH3, CH2CH3, and —CH2NHCOZCH2CH3;
xii) —(CR2023R202b)bN(R201)2; for example, —NH2, —CH2NH2, —NHCH3,
—CH2NHCH3, —N(CH3)2, and —CH2N(CH3)2;
xiii) halogen; —F, —Cl, —Br, and —I;
xiv) —(CR202aR202b)bCN;
xv) —(CR202aR202b)bNOZ;
xvi) —(CHj,Xk,)aCHJ-Xk; wherein X is halogen, the index j is an integer from 0 to
2,j + k = 3; the indexj’ is an integer from 0 to 2, j’ + k’ = 2; for example,
—CH2F, —CHF2, —CH2CH2F, —CH2CHF2, —CF3, —CCl3, or —CBr3;
xvii) —(CR202aR202b)bSR201, —SH, —CHZSH, —SCH3, H3, —SC6H5, and
6H5;
xviii) —(CR2023R202b)bSOZR201; for example, —SOzH, —CHZSOZH, 3,
—CHZSOZCH3, —SOZC6H5, and —CHZSOZC6H5; and
xix) —(CR2023R202b)bSO3R201; for example, —so3H, —CHZSO3H, —SO3CH3,
—CHZSO3CH3, —SO3C6H5, and —CH2803C6H5;
wherein each R201 is independently hydrogen, C1—C6 linear, C3—C6 branched, or C3—C6 cyclic
alkyl, phenyl, benzyl, heterocyclic, or aryl; or two R201 units can be taken together to
form a ring comprising 3-7 atoms; R202a and R20% are each independently hydrogen or C1—
C4 linear or C3-C4 ed alkyl; the index “b” is from 0 to 4.
For the purposes of the present disclosure the terms “compound,” “analog,” and
“composition of matter” stand y well for each other and are used interchangeably
throughout the specification. The disclosed compounds include all enantiomeric forms,
diastereomeric forms, salts, and the like.
The compounds disclosed herein include all salt forms, for example, salts of both
basic groups, inter alia, amines, as well as salts of acidic , inter alia, carboxylic
acids. The following are non-limiting examples of anions that can form salts with
protonated basic groups: de, bromide, iodide, e, bisulfate, carbonate,
bicarbonate, phosphate, formate, acetate, propionate, butyrate, te, lactate, oxalate,
malonate, e, ate, tartrate, fumarate, citrate, and the like. The following are
non-limiting examples of cations that can form salts of acidic groups: ammonium, sodium,
lithium, potassium, calcium, magnesium, bismuth, lysine, tromethamine, meglumine and
the like.
The disclosed process can be used to prepare compounds having the formula:
/ OH
OH 0
wherein R and R1 are further defined herein.
Compounds having the formula:
\N O
/ S‘Liou
OH 0
wherein L is a linking group defined herein. have been found to exhibit prolyl hydroxylasc
inhibition (antagonism). Compounds of this formula have also been found to stabilize
hypoxia ble factor-2 alpha (HIP-2a). It has also been found that esters and amides
having the formula:
o \
N o
H i 3 i H l 4
N R w R
‘1. 0’ / I“
L If
on o and on o R5
can hydrolyze in vivo, in vitro and ex vivo to the ponding carboxylic acids shown
above. As such, these esters and amides are referred to herein as "prodrugs."
In a ular embodiment, the present invention provides a process for preparing a
compound having the formula:
wherein R1 is chosen from:
i) substituted or unsubstituted C6 or C10 aryl; or
ii) substituted or unsubstituted C1-C9 heteroaryl;
L is a linking unit having the formula:
—(CR7°R7")n—
R7a and R7” are each independently:
i) hydrogen; or
ii) C1-C6 linear, C3-C6 ed or C3-C5 cyclic alkyl;
R8 is chosen from hydrogen, methyl, or ethyl; and
the index n is an integer from 1 to 4;
13 (followed by 13A)
or a pharmaceutically acceptable salt thereof,
comprising:
A) reacting a boronic acid or ester having the a:
wherein Y is OR2°, R20 is hydrogen or C1-C6 linear, C3-C6 branched, or C3-C6
cyclic alkyl, or two OR20 units can be taken together to form a 5-member to 7-
member C3-C10 cyclic ester, with a 3,5-dihalocyanopyridine having the
each Z is independently chloro or bromo, in the presence of a catalyst, to form
a 5-aryl or 5-heteroarylhalocyanopyridine having the formula:
B) reacting the S-aryl or 5-heteroarylhalocyanopyridine formed in step (A)
with an alkoxide anion having the formula:
9 0R2
wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-a1y1 or
—heteroa1yl—3-alkoxy—2-cyanopyridine having the formula:
13A (followed by 133)
C) reacting the S-aryl or 5-heteroaryl-3—alkoxycyanopyridine formed in step
03) with an acid to form a 5-aryl or 5-heteroarylhydroxycarboxypyridine
having the formula:
/ OH
OH 0 'and
D) reacting the S-aryl or 5-heteroa1yl-3—hydroxycarboxypyridine formed in
step (C) with an amino acid having the formula:
N com
H \(CR7HR7h)n/ “
In another embodiment, the present invention provides a process for preparing a compound
having the formula:
N {:8 O
/ N
\(CR7aR7b)nAX
0H 0
wherein A is a ring chosen from:
i) substituted or unsubstituted C6 or C10 aryl; or
ii) substituted or unsubstituted C1-C9 aryl;
Rlo represents one or more ndently chosen optionally present substitutions for
hydrogen;
X is chosen from:
i) —OH;
ii) —0R3;
iii) ; and
iv) —OM1;
13B (followed by 13C)
R3 is C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; C2-C12 linear, C3—C12
branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic
alkynyl, or benzyl;
R4 and R5 are each independently hydrogen, C1-C12 linear, C3-C12 branched or C3-C12
cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic l; or C2-C12 linear,
C3-C12 branched or C3-C12 cyclic alkynyl; benzyl; or R4 and R5 can be taken together
with the nitrogen atom to form a 3 to 10 member ring, wherein the ring can optionally
contain one or more heteroatoms chosen from oxygen (0), nitrogen (N), or sulfur (S);
M1 is a pharmaceutically acceptable cation;
R7” and R7” are each independently:
i) hydrogen; or
ii) C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl;
R8 is chosen from hydrogen, , or ethyl; and
the index n is an r from 1 to 4;
or a pharmaceutically acceptable salt thereof,
comprising:
A) reacting a boronic acid or ester having the a:
R'° B
wherein Y is ORZO, R20 is en or C1-C6 linear, C3-C6 branched, or C3-C6
cyclic alkyl, or two OR20 units can be taken together to form a S-member to 7-
member C3-C1o cyclic ester, with a 3,5-dihalocyanopyridine having the
formula:
each Z is independently chloro or bromo, in the presence of a catalyst, to form
a 5-aryl or 5-heteroaryl—3-halocyanopyridine having the formula:
13C (followed by 130)
B) reacting the S-aryl or 5-heteroarylhalocyanopyridine formed in step (A)
with an alkoxide anion having the formula:
9 0R2
n R2 is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-ary1 or
—heteroaryl—3-alkoxy—2-cyanopy1idine having the formula:
C) reacting the 5-aryl or 5-heteroaryl—3-alkoxy—2-cyanopyridine formed in step
(B) with an acid to form a 5-aryl or 5-heteroarylhydroxycarboxypyridine
having the formula:
/ OH
OH O ;and
D) reacting the S-aryl or 5—heteroaryl-3—hydroxy-2—carboxypyridine formed in
step (C) with a compound having the formula:
R8 0
H \(CR7aR7b))L Xn
13D (followed by 13E)
13E wed by 14)
WO 70377
When a ring is formed from R4 and R5 and the ring contains a ring en other
than the nitrogen atom to which R4 and R5 are bonded, then the nitrogen atom can have the
form —NR9— or =N—, wherein R9 can be hydrogen or methyl. Non-limiting examples
of this embodiment includes compounds having the formula:
\N R1
0 \ O
/ \L N/fi / N\L N/\N
0R2 O
K/NH and OR2 0 K/
In one aspect, X is hydroxyl, —OH.
In a further aspect, X is —OR3. One embodiment of this aspect relates to X units
wherein R3 is C1-C6 linear alkyl, for example, methyl (C1), ethyl (C2), n-propyl (C3), n-butyl
(C4), n-pentyl (C5), and n-hexyl (C6). Non-limiting examples include the methyl ester, the
ethyl ester, the n-propyl ester, and the like.
Another embodiment of this aspect relates to X units wherein R3 is C3-C6 branched
alkyl non-limiting examples of which include iso—propyl (C3), sec—butyl (C4), iso—butyl (C4),
tert—butyl (C4), l-methylbutyl (C5), 2-methylbutyl (C5), 3-methylbutyl (C5), and 4-
methylpentyl (C6).
A further embodiment of this aspect s to X units wherein R3 is C3—C6 cyclic
alkyl, for example, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), and cyclohexyl (C6).
In r aspect, X is —NR4R5. One embodiment of this aspect relates to X units
wherein R4 and R5 are both en; —NH2_
A further embodiment of this aspect relates to X units wherein R4 and R5 are
independently chosen from hydrogen, C1-C4 linear alkyl, C3-C4 branched alkyl, or C3-C4
cyclic alkyl, for e, methyl (C1), ethyl (C2), n-propyl (C3), iso-propyl (C3), n-butyl
(C4), sec—butyl (C4), tyl (C4), and tert—butyl (C4). Non-limiting es of this
embodiment include —NH2, —NHCH3, —N(CH3)2, —NHC2H5, —N(C2H5)2, and —
N(CH3)(C2H5).
L is a linking unit having the formula —(CR7aR7b)n— wherein R7a and R7b can be
independently chosen from hydrogen, C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl.
The index n is an integer from 1 to 4.
In one aspect of L units, R7a and R7b are both en and the index n is an r
from 1 to 4, i.e., —CH2— (methylene), —CH2CH2— (ethylene), —CH2CH2CH2— (propylene),
and —CH2CH2CH2CH2— (butylene). One ion of L units according to this aspect relates
to nds having the formula:
R1 R] R1
\ o \ \
N N 0 N o
/ E\Jkon mfi$ow mfidkmfiw
OR2 o OR2 o and OR2 o
, ,
A further aspect of L units relates to L units n R7a and R7b are independently
chosen from hydrogen, methyl (C1), ethyl (C2), n-propyl (C3), and iso-propyl (C3) and the
index n is an integer from 1 to 4. One embodiment of this aspect relates to L units wherein
R7a is hydrogen and R7b is chosen from methyl (C1), ethyl (C2), n—propyl (C3), and iso—
propyl (C3), and the index n is an integer from 1 or 3. Non-limiting examples of this
embodiment includes —CH(CH3)—, —CH2CH(CH3)—, —CH(CH3)CH2—, —CH(CH3)CH2CH2—,
—CH2CH(CH3)CH2—, and —CH2CH2CH(CH3)—.
A yet further aspect of L units relates to L units wherein R7a and R7b are
independently chosen from methyl (C1), ethyl (C2), yl (C3), and iso-propyl (C3) and
the index n is an integer from 1 to 4. A non-limiting example of this aspect has the formula
—C(CH3)2—.
In a still further aspect of L units, L units can be derived from the reaction of an
amino acid with a 5—aryl or 5—heteroaryl—3—hydroxy—2—carboxypyridine as described herein
below in the disclosure of process step D. One embodiment of this aspect of L relates to L
units n R7b is hydrogen and R7a is chosen from hydrogen, methyl, iso—propyl, iso—
butyl, sec-butyl, hydroxymethyl, l-hydroxyethyl, thiomethyl, 2-(methylthio)ethyl, benzyl,
(4-hydroxyphenyl)methyl, indolylmethyl, imidazolylmethyl, 3-gunidinylpropyl, 4-
aminobutyl, carboxymethyl, 2—carboxyethyl, ide, or R8 and R7a can be taken together
to form a idinyl ring, for example, when proline is reacted with the 5-aryl or 5—
heteroarylhydroxycarboxypyridine.
The index n can be any integer from 1 to 4, for example n can equal 1, n can equal 2,
n can equal 3, and n can equal 4.
R8 is en, methyl (C1) or ethyl (C2). In one aspect R8 is hydrogen. In a further
aspect R8 is methyl (C1). In another aspect R8 is ethyl (C2).
R1 Units
R1 units are chosen from:
i) substituted or unsubstituted C6 or C10 aryl; and
ii) substituted or unsubstituted C1—C9 heteroaryl.
Non-limiting examples of tutions for a hydrogen atom on R1 units, or
alternatively an R10 unit when R1 is represented by an A ring, include:
i) C1—C12 linear, C3—C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl;
for e, methyl (C1), ethyl (C2), ethenyl (C2), ethynyl (C2), n-propyl
(C3), iso—propyl (C3), cyclopropyl (C3), 3—propenyl (C3), l—propenyl (also 2—
methylethenyl) (C3), isopropenyl (also 2-methylethenyl) (C3), prop-2—ynyl
(also propargyl) (C3), —l—yl (C3), n—butyl (C4), sec—butyl (C4), iso—
butyl (C4), tert—butyl (C4), cyclobutyl (C4), 4—yl (C4), entyl (C5),
cyclohexyl (C6);
ii) C6 or C10 aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen- l -yl (C10) or naphthylenyl (C10));
iii) C7 or C11 alkylenearyl; for example, benzyl, 2—phenylethyl, naphthylen-2—
ylmethyl;
iV) C1—C9 heterocyclic rings; as described herein below;
C1-C9 heteroaryl rings; as described herein below;
Vi) —(CR1023R102b)aOR101; for e, —OH, , —OCH3, —CHZOCH3,
—OCH2CH3, —CHZOCH2CH3, —OCH2CH2CH3, and —CH20CH2CH2CH3;
Vii) —(CR1023R102b)aC(O)R101; for example, —COCH3, —CH2COCH3,
—COCH2CH3, —CH2COCH2CH3, —COCH2CH2CH3, and
—CH2COCH2CH2CH3;
viii) —(CR1023R102b)aC(O)OR101; for example, —COzCH3, —CH2COZCH3,
—COzCH2CH3, —CH2COzCH2CH3, —COzCH2CH2CH3, and
—CH2COZCH2CH2CH3;
ix) —(CR1ozaRlozb)aC(O)N(R101)2; for example, —CONH2, —CH2CONH2,
—CONHCH3, —CH2CONHCH3, —CON(CH3)2, and —CH2CON(CH3)2;
—(CR1023R102b)aN(R101) C(O)R101; for example, —NHCOCH3,
—CH2NHCOCH3, —NHCOCH2CH3, and COCH2CH3;
xi) —(CR102aR102b),N(R101) C(O)2R101; for example, —NHCOZCH3,
—CH2NHC02CH3, —NHCOzCH2CH3, and —CH2NHCOzCH2CH3;
xii) —(CR1023R102b)aN(R101)2; for example, —NH2, —CH2NH2, ,
—CH2NHCH3, —N(CH3)2, and CH3)2;
xiii) halogen; —F, —Cl, —Br, and —I;
xiv) _(CR102aR102b)aCN;
xv) 2aR102b)aNOZ;
xvi) —(CHj,Xk,)aCHJ-Xk; wherein X is halogen, the index j is an integer from 0 to
2,j + k = 3; the indexj’ is an integer from 0 to 2, j’ + k’ = 2; for example, —
CHZF, —CHF2, —CF3, —CCl3, or —CBr3;
xvii) —(CR102aR102b),SR101, —SH, —CHZSH, —SCH3, —CHZSCH3, , and
—CHZSC6H5;
xviii) —(CR102aR102b)aSOZR101; for example, —SOzH, —CstOzH, —SOzCH3,
—CHZSOZCH3, —SOZC6H5, and —CHZSOZC6H5; and
xix) —(CR1023R102b)aSO3R101; for example, —so3H, —CHZSO3H, —SO3CH3,
3CH3, —SO3C6H5, and —CHZSO3C6H5; or
xx) two substitutions for hydrogen can be taken together to form a substituted or
unsubstituted C2—C8 heterocyclic ring, n the ring substitution can be
one or more of the substitutions defined in (i) to (xix) herein above and the
ring can comprise one or more heteroatoms chosen from oxygen (0) sulfur
(S), or nitrogen (N);
wherein each R101 is independently hydrogen, substituted or tituted C1—C6 linear, C3—
C6 branched, or C3—C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101
units can be taken together to form a ring comprising 3-7 atoms; R102a and R10% are each
independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index “a” is from 0 to
4.
Stated in another way, the disclosed process relates to the formation of compounds
haVing the formula:
/ R
OH 0
wherein the A ring represents R1 units wherein R1 can be:
i) substituted or unsubstituted C6 or C10 aryl; and
ii) substituted or unsubstituted C1—C9 heteroaryl;
wherein the substitutes for en atoms on the A ring are one or more R10 units that are
independently chosen and further described herein.
One aspect of R1 relates to substituted or tituted C6 aryl, i.e., substituted or
tituted phenyl. A first embodiment of this aspect relates to R1 equal to phenyl, for
example, compounds having the formula:
A further aspect of R1 relates to R1 units that are substituted phenyl having the
formula:
R10 |
\ \N
/ R
OH 0
n R10 represents from 1 to 5 independently chosen substitutions for hydrogen; or two
R10 units can be taken together to form a tuted or unsubstituted C4—C8 cycloalkyl ring,
a substituted or unsubstituted C6 aryl ring (phenyl), a substituted or unsubstituted C2—C8
heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the
heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen
from oxygen (0), nitrogen (N), or sulfur (S).
One embodiment of this aspect of R1 units relates to compounds comprising
substitutions on R1 of one or more units independently chosen from:
i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl;
ii) C1-C12 , C3-C12 ed or C3-C12 cyclic alkoxy; and
iii) halogen: —F, —Cl, —Br, and —1.
One iteration of this embodiment relates to compounds comprising one or more R10
units that are halogen, thereby forming the following non-limiting examples of R1 units: 2-
fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5—
difluorophenyl, 2-chlorophenyl, rophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-
dichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 3,5-dichlorophenyl,
2,3,4-trifluorophenyl, trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl,
trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-
dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-
trichlorophenyl, 3,4,5-trichlorophenyl, and 2,4,6-trichlorophenyl.
WO 70377
A further iteration relates to compounds comprising one or more R10 units that are
C1—C4 linear, C3—C4 branched or C3-C4 cyclic alkyl, thereby forming the following non-
limiting examples of R1 units: 2—methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,3-
dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-
dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5-
trimethylphenyl, 2,4,6-trimethylphenyl, 2—ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-
diethylphenyl, ethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl,
triethylphenyl, triethylphenyl, 2,3,6-triethylphenyl, triethylphenyl, 2,4,6-
triethylphenyl, 2—isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.
r iteration relates to compounds comprising one or more R10 units that are
C1—C4 linear, C3—C4 branched or C3-C4 cyclic alkoxy, thereby forming the following non-
limiting examples of R1 units: 2—methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-
dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-
oxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6-
trimethoxyphenyl, 2,4,5-trimethoxyphenyl, trimethoxyphenyl, 2—ethoxyphenyl, 3-
ethoxyphenyl, 4-ethoxyphenyl, 2,3-diethoxyphenyl, 2,4-diethoxyphenyl, 2,5-
diethoxyphenyl, 2,6-diethoxyphenyl, 3,4-diethoxyphenyl, 2,3,4-triethoxyphenyl, 2,3,5-
triethoxyphenyl, triethoxyphenyl, 2,4,5-triethoxyphenyl, 2,4,6-triethoxyphenyl, 2-
isopropoxyphenyl, 3-isopropoxyphenyl, and 4-isopropoxyphenyl.
A yet still further iteration relates to compounds comprising one or more R10 units
that comprise at least one of each substitution chosen from C1-C4 linear or halogen, thereby
forming the following non-limiting examples of R1 units: 2—chloromethylphenyl, 2-
chloromethylphenyl, 2-chloromethylphenyl, romethylphenyl, 3-chloro
methylphenyl, 3-chloromethylphenyl, 3-chloromethylphenyl, 3-chloromethyl-
phenyl, 2-fluoro-3 -methylphenyl, 2—fluoromethylphenyl, romethylphenyl, 2-
fluoromethylphenyl, 3-fluoro-2—methylphenyl, 3-fluoromethylphenyl, o
methylphenyl, and 3-fluoromethylphenyl.
One embodiment of this aspect of R1 units relates to compounds comprising one or
more R10 units independently chosen from:
i) 2aR102b)aCN;
ii) —(CR102aR102b)aNOZ;and
iii) —(CHj,Xk,)aCHJ-Xk; wherein X is halogen, the index j is an integer from 0 to
2,j + k = 3; the indexj’ is an integer from 0 to 2,j’ + k’ = 2.
On ion of this embodiment relates to compounds comprising one or more R10
units that are —(CH2)aCN, wherein the index a is 0 or 1, thereby forming the following non-
limiting es of R1 units: 2—cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-
(cyanomethyl)phenyl, 3-(cyanomethyl)phenyl, 4-(cyanomethyl)phenyl, 2,3-dicyanophenyl,
3,4-dicyanophenyl, and 3,5-dicyanophenyl.
Another iteration of this embodiment relates to compounds comprising one or more
R10 units that are —(CH2)aN02, n the index a is 0 or 1, thereby forming the following
non-limiting examples of R1 units: 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2-
(nitromethyl)phenyl, 3-(nitromethyl)phenyl, 4-(nitromethyl)phenyl, 2,3-dinitrophenyl, 3,4-
dinitrophenyl, and 3,5-dinitrophenyl.
A further iteration of this embodiment relates to compounds comprising one or more
R10 units that are —CHJ-Xk; wherein X is halogen, the index j is an integer from 0 to 2, j + k
= 3, n the index a is 0 or 1, y forming the following miting examples of
R1 units: —CH2F, —CH2CH2F, —CHF2, —CH2CHF2, —CF3, —CH2CF3, —CHFCH2F, —CF2CHF2,
—CF2CF3, —CH2Cl, —CH2CH2Cl, —CHClz, —CH2CHClz, —CCl3, —CH2CCl3, —CHClCH2Cl,
—CClzCHClz, and —CClzCCl3.
One embodiment of this aspect of R1 units relates to compounds comprising one or
more R10 units independently chosen from:
i) —(CR102aR102b)aN(R101)2;
ii) —(CR1ozaRlozb)aC(O)N(R101)2; and
iii) —(CR1ozaRl02b)aN(R101)C(O)2R101.
One iteration of this embodiment relates to compounds comprising one or more R10
units that are —(CR102aR102b)aN(R101)2, wherein the index a is 0 or 1, thereby forming the
following miting examples of R1 units: 2—aminophenyl, ophenyl, 4-
aminophenyl, 2,3-diaminophenyl, 3,4-diaminophenyl, aminophenyl, 2-
methylaminophenyl, 3-methylaminophenyl, 4-methylaminophenyl, 2,3-
(dimethylamino)phenyl, 3,4-(dimethylamino)phenyl, 3,5-(dimethylamino)phenyl, 2,3,4-
triaminophenyl, 2,3,5-triaminophenyl, 2,3,6-triaminophenyl, 2,4,5-triaminophenyl, 2,4,6-
triaminophenyl, 2,4-(dimethylamino)phenyl, 2,5-(dimethylamino)phenyl, 2,6-
(dimethylamino)phenyl, 3,4-(dimethylamino)phenyl, 2,3,4-(dimethylamino)phenyl, 2,3,5-
(dimethylamino)phenyl, 2,3,6-(dimethylamino)phenyl, 2,4,5-(dimethylamino)phenyl, 3,4,5-
(dimethylamino)phenyl, and 2,4,6-(dimethylamino)phenyl.
Another iteration of this embodiment relates to compounds comprising one or more
R10 units that are —(CR1ozaRlozb)aC(O)N(R101)2, wherein R101 is chosen from hydrogen, C1—
C6 linear, C3-C6 ed alkyl or C3-C6 cyclic alkyl, and the index a is 0 or 1, thereby
forming the following non-limiting examples of R1 units: —C(O)NH2, —C(O)NHCH3,
—CH2C(O)NHCH3, —C(O)N(CH3)2, —CH2C(O)N(CH3)2, —C(O)NHCH2CH3,
—CH2C(O)NHCH2CH3, —C(O)N(CH2CH3)2, O)N(CH2CH3)2, —C(O)NHCH(CH3)2,
—CH2C(O)NHCH(CH3)2, —C(O)N[CH(CH3)2]2, and —CH2C(O)N[CH(CH3)2]2.
Another iteration of this embodiment relates to compounds comprising one or more
R10 units that are —(CR1ozaRlozb)aC(O)N(R101)2, n two R101 units are taken together to
form a ring haVing from 3 to 7 atoms and the index a is 0 or 1, thereby forming R1 units
haVing, for example, the formulae:
51.,
A further iteration of this embodiment relates to compounds comprising one or more
R10 units that are —(CR1ozaRl02b)aN(R101)C(O)2R101; n R101 is chosen from hydrogen,
C1-C6 linear, C3-C6 branched alkyl or C3-C6 cyclic alkyl, and the index a is 0 or 1, y
forming the ing non-limiting examples of R1 units: —NHC(O)CH3,
—CH2NHC(O)CH3, —NHC(O)CH2CH3, —CH2NHC(O)CH2CH3, —NHC(O)CH2CH2CH3,
—CH2NHC(O)CH2CH2CH3, —NHC(O)(cyclopropyl), and —CH2NHC(O)(cyclopropyl).
Another aspect of R1 relates to R1 units that are substituted or unsubstituted C1—C9
heteroaryl. One embodiment of this aspect relates to R1 equal to C1-C9 heteroaryl, for
example, compounds having the a:
/ R
OH O
wherein ring A ent a C1-C9 heteroaryl unit non-limiting examples of which include:
l,2,3,4—tetrazolyl (C1), [1,2,3]triazolyl (C2), ]triazolyl (C2), [1,2,4]oxadiazolyl (C2),
]oxadiazolyl (C2), [1,2,4]thiadiazolyl (C2), [l,3,4]thiadiazolyl (C2), isothiazolyl (C3),
thiazolyl (C3), imidazolyl (C3), oxazolyl (C3), isoxazolyl (C3), lyl (C3), pyrrolyl (C4),
furanyl (C4), thiophenyl (C4), triazinyl (C3), pyrimidinyl (C4), pyrazinyl (C4), pyridazinyl
(C4), pyridinyl (C5), purinyl (C5), xanthinyl (C5), hypoxanthinyl (C5), benzimidazolyl (C7),
indolyl (Cg), quinazolinyl (Cg), quinolinyl (C9), and isoquinolinyl (C9).
In a r embodiment of this aspect the C1—C9 heteroaryl unit can be bonded to the
core pyridine ring at any suitable position, non-limiting examples of which include:
N§ \
_ $193 _§_<\N,E,
-3 / IfH §\N /§N _§_<§‘N
—3 \
7 +13%; \NJ;
iii)
—Hi 3“?»)1] NH
iV)
Mléfl,NH
We ifli iv“\ 0\
vii)
N\ 0\
—H\N])_ -§—<\Nj“
viii)
-§—<\ l
N ;
M1£0
_§_<j _§@;
H? -%i, ‘HJ
xii)
HZ]. if; —34©i
xiii)
-§—<\:1%—<\:\j“.
xiv)
-3—<\:l_
_§—<\Nj£>E <\Njk/:L,.s{; E E “if E a
~ <\Nj£> <\Njij/
m
xvi)
«do <1;N N <1:N N N “UL
S ; S (SE; S ; S ; <0S
xvii)
Er: <1; myN N N N <0N ”BL
0 ; O .52; O ; O ; O
xviii)
woodedE E E E goE m
xiv)
E «NI/IN\ 9'2 All?! N\ E N\ E N\
; <11ng _§_<\NL1; <\N I /1
«NU ; <30 EENJQN; GQN
“Y” ;and
xvi)
E J1“?! E E «NUN\t1'7. N\ N\ N\
; <E31); _3—<\ND ; <\N:£2
Another embodiment of this aspect relates to R1 units equal to substituted C1—C9
heteroaryl, for e, compounds having the formula:
/ R
01-10
wherein ring A represent a C1-C9 heteroaryl unit non—limiting examples of which include:
4-tetrazolyl (C1), [1,2,3]triazolyl (C2), [1,2,4]triazolyl (C2), [1,2,4]oxadiazolyl (C2),
[1,3,4]oxadiazolyl (C2), ]thiadiazolyl (C2), [1,3,4]thiadiazolyl (C2), isothiazolyl (C3),
thiazolyl (C3), imidazolyl (C3), oxazolyl (C3), isoxazolyl (C3), pyrazolyl (C3), pyrrolyl (C4),
furanyl (C4), thiophenyl (C4), triazinyl (C3), pyrimidinyl (C4), pyrazinyl (C4), pyridazinyl
(C4), pyridinyl (C5), purinyl (C5), xanthinyl (C5), nthinyl (C5), benzimidazolyl (C7),
indolyl (Cg), quinazolinyl (Cg), inyl (C9), and isoquinolinyl (C9).
Non-limiting es of tutions for a hydrogen atom on R1 C1-C9 heteroaryl
units include:
i) C1—C12 linear, C3—C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl;
methyl (C1), ethyl (C2), ethenyl (C2), ethynyl (C2), n—propyl (C3), iso—propyl
(C3), cyclopropyl (C3), 3—propenyl (C3), l—propenyl (also ylethenyl)
(C3), isopropenyl (also 2—methylethen—2—yl) (C3), prop—2—ynyl (also
propargyl) (C3), propyn-l-yl (C3), n—butyl (C4), sec—butyl (C4), iso—butyl (C4),
tert—butyl (C4), cyclobutyl (C4), 4—yl (C4), cyclopentyl (C5), cyclohexyl
(C6);
ii) C6 or C10 aryl; for example, phenyl, naphthyl (also referred to herein as
naphthylen- l -yl (C10) or naphthylenyl (C10));
iii) C7 or C11 alkylenearyl; for example, benzyl, 2—phenylethyl, naphthylen-2—
ylmethyl;
iV) C1—C9 heterocyclic rings; as described herein below;
C1-C9 heteroaryl rings; as described herein below;
Vi) 23R102b)aOR101; for example, —OH, —CHZOH, —OCH3, H3,
—OCH2CH3, —CH20CH2CH3, —OCH2CH2CH3, and —CH20CH2CH2CH3;
Vii) —(CR102aR102b)aC(O)R101; for example, —COCH3, —CH2COCH3,
—COCH2CH3, —CH2COCH2CH3, —COCH2CH2CH3, and
—CH2COCH2CH2CH3;
viii) —(CR1023R102b)aC(O)OR101; for example, —C02CH3, —CH2COZCH3,
—COzCH2CH3, —CH2COzCH2CH3, 2CH2CH3, and
—CH2C02CH2CH2CH3;
ix) —(CR1ozaRlozb)aC(O)N(R101)2; for example, —CONH2, —CH2CONH2,
—CONHCH3, —CH2CONHCH3, —CON(CH3)2, and —CH2CON(CH3)2;
WO 70377
x) —(CR102aR102b)aN(R101) C(0)R101, for example, —NHCOCH3,
—CH2NHCOCH3, —NHCOCH2CH3, and —CH2NHCOCH2CH3;
xi) —(CR1023R102b)aN(R101) C(O)2R101; for example, —NHCOZCH3,
COZCH3, CH2CH3, and —CH2NHCOZCH2CH3;
xii) —(CR102aR102b)aN(R101)2, for example, —NH2, —CH2NH2, —NHCH3,
—CH2NHCH3, —N(CH3)2, and —CH2N(CH3)2;
xiii) halogen; —F, —Cl, —Br, and —I;
xiv) _(CR102aR102b)aCN;
xv) _(CR102aR102b)aNOZ;
xvi) —(CHjana)aCHJ-Xk; wherein X is halogen, the index j is an integer from 0 to
2,j + k = 3; the indexj’ is an integer from 0 to 2, j’ + k’ = 2; for example, —
CHZF, —CHF2, —CF3, —CCl3, or —CBr3;
xvii) 2aR102b),SR101, —SH, —CHZSH, —SCH3, —CHZSCH3, —SC6H5, and
—CH2$C6H5;
xviii) —(CR102aR102b)aSOZR101; for example, —SOzH, —CHZSOZH, —SOZCH3,
—CHZSOZCH3, —SOzC6H5, and —CHZSOZC6H5; and
xix) —(CR1023R102b)aSO3R101; for example, —so3H, —CHZSO3H, 3,
—CH2803CH3, —SO3C6H5, and —CHZSO3C6H5;
wherein each R101 is independently hydrogen, substituted or unsubstituted C1—C6 linear, C3—
C6 branched, or C3—C6 cyclic alkyl, , benzyl, heterocyclic, or heteroaryl; or two R101
units can be taken together to form a ring comprising 3-7 atoms; R102a and R10% are each
independently hydrogen or C1-C4 linear or C3-C4 branched alkyl; the index “a” is from 0 to
Non-limiting examples of substituted C5-C9 R1 heteroaryl units include 2—
thiazolyl, lthiazolyl, 2—(n-propyl)thiazolyl, 2—(is0-propyl)thiazolyl,
4,5-dimethylthiazolyl, 4-ethylmethylthiazolyl, 4-methylethylthiazol-2—yl, 4,5-
diethylthiazolyl, 3-methyl-l,2,4-oxadiazolyl, 4,5-dimethylimidazol-2—yl, 4-ethyl
methylimidazol-2—yl, 4-methylethylimidazolyl, 4,5-diethylimidazolyl, 2,5-
dimethylthiazolyl, 2,4-dimethylthiazolyl, 3-methyl-1,2,4-oxadiazolyl, 4,5-
dimethyloxazol-2—yl, 4-ethylmethyloxazol-2—yl, ylethyloxazol-2—yl, 4,5-
loxazolyl, 2-methyloxazolyl, 2-ethyloxazolyl, 2—(n-propyl)oxazolyl, 2-
(iso-propyl)oxazolyl, 2-methyloxazolyl, 2—ethyloxazolyl, 2-(n-propyl)oxazolyl,
2-(is0-propyl)oxazolyl, 5-methyl[l,2,4]oxadiazolyl, 5-ethyl[l,2,4]—oxadiazolyl, 5-
propy1[1,2,4]0xadiazol-3 -y1, 5-cyclopr0py1[1,2,4]0xadiazoly1, y1[1,2,4]0xadiazol-
-y1, 3-ethy1[1,2,4]0xadiazoly1, r0py1)[1,2,4]0xadiazoly1, 3-(is0—
propy1)[1,2,4]0xadiazoly1, 2,5-dimethy1thiazoly1, 2,4-dimethy1thiazoly1, 4-
ethylthiazol-Z-yl, 3-methy1—1,2,4-0xadiazoly1, 4,5-dimethy1pyrimidin-2—y1, 4,5-
diethylpyrimidin-Z-yl, 4-methy1—5-ethy1—pyrimidin-2—y1, 4-ethy1—5-methy1—pyrimidiny1, 4-
(thiopheny1)pyrimidin-2—y1, 5-(thi0pheny1)pyrimidin-2—y1, 4-(thi0phen
y1)pyrimidiny1, and 5-(thi0pheny1)pyrimidin-3 -y1.
Non—limiting examples of substituted C2—C4 5—member heteroaryl rings include:
.g 0\
MN H C
3 MN
CH3
7 x“;
\ N 5‘“
“'1"
CH3,
iii)
DN\N
CH3;
iv)
55" OCH 3"
WAN—g WAN—g0C H / 3 / 2 5
N§N O N§N O
551%” 0cm g:bII c2115
N§N O N§N O
7 ;
J‘m J‘w
\ O 5 O
N“ /N\)J\ N‘3 ,N
N OCH3 N OC2H5
Vii)
viii)
“741.
Ucm MDN
7 '
A yet further aspect of R1 units relates to rings comprising two R10 substitutions for
hydrogen that are taken together to form a substituted or unsubstituted C2—C8 heterocyclic
ring. One embodiment of this aspect relates to R1 units wherein two R10 units are taken
together to form a tuted or unsubstituted C7—C9 heterocyclic R1 ring system wherein
the heterocyclic ring formed by the two R10 substitutions contains one or more nitrogen
atoms. Non-limiting iterations of this ment include R1 units haVing the formulae:
CO co CO\ J‘IA g flandHNcoft.
7 ,
Another embodiment of this aspect relates to R1 units wherein two R10 units are
taken together to form a substituted or unsubstituted C7—C9 heterocyclic R1 ring system
wherein the heterocyclic ring formed by the two R10 substitutions contains one or more
oxygen atoms. miting iterations of this embodiment include R1 units haVing the
formulae:
<ZI>ng<O [O
“i" [:Dys: m
and I
R2 Units
R2 units are chosen from C1-C12 linear alkyl or C3-C12 branched alkyl. In one
embodiment R2 can represent hydrogen. In another embodiment, R2 is C1-C4 linear alkyl.
miting examples include methyl, ethyl and n-propyl. In one example, R2 is .
R2 units relate to the de unit haVing the formula:
9 OR2
that is used in the process disclosed herein. As it relates to the alkoxide, the alkoxide can be
derived from any suitable , i.e., sodium methoxide, lithium ethoxide, and the like
which the formulator can choose.
A further aspect of the present disclosure relates to a process for preparing
intermediates having the formula:
/ OH
OH 0
wherein Rlis the same as defined herein above. This aspect also includes salts of acids, for
example, compounds having the formula:
wherein M is a salt forming cation and N represents the cationic charge on M and the
number of corresponding anionic units of the disclosed intermediates. The M units can
comprise in one embodiment inorganic cations, inter alia, ammonium, sodium, lithium,
potassium, calcium, magnesium, bismuth, and the like. In another embodiment, M units
can comprise organic cation forming units, inter alia, lysine, ine, glycine, alanine, or
other amino acids, basic c compounds, inter alia, methylamine, dimethylamine,
trimethylamine, and the like.
Another aspect of the present sure relates to a process for preparing
intermediates having the formula:
wherein W is a salt g anion and Y represents the anionic charge on W and the
number of corresponding number of the disclosed intermediates in this salt form. The W
units can comprise in one embodiment inorganic anions, inter alia, chloride, bromide,
iodide, e, bisulfate, ate, bicarbonate, phosphate, and the like. In another
embodiment, W units can comprise organic anion forming units, inter alia, e, acetate,
propionate, butyrate, pyruvate, lactate, e, malonate, maleate, succinate, tartrate,
fumarate, citrate, and the like.
In one , the disclosed prolyl hydroxylasc inhibitors can be isolated as a
pharmaceutically acceptable salt having the formula:
\N o
N I H
. A M‘N
/ I\
‘L 09
OH 0
wherein M is a salt forming cation and N represents the cationic charge on M and the
number of ponding anionic units present in the salt.
In a particular embodiment, the present invention provides a compound having the
formula:
\N o
N H A M+N
/ N
‘L 06
0H 0
wherein M is a salt forming cation and N represents the cationic charge on M;
A is C10 aryl;
Rlo units represent at least one optionally present substitutions for a ring hydrogen
atom; or two Rlo units can be taken together to form a substituted or unsubstituted C4—
Cs cycloalkyl ring, a tuted or unsubstituted C6 or C10 aryl ring, a substituted or
unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5
heteroaryl ring, n the heterocyclic and heteroaryl rings comprise one or more
hetero atoms independently chosen from oxygen (0), nitrogen (N), or sulfur (S).
L is a linking unit having the formula:
—(CR7’R7")n—
R7a and R7” are each independently:
i) hydrogen; or
(followed by 30A)
ii) C1-C6 linear, C3-C6 ed or C3-C6 cyclic alkyl; and
the index n is an integer from 1 to 4.
30A (followed by 31)
One iteration of this embodiment relates to cations wherein each of Ra, Rb and R0 are
hydrogen or C1-C12 linear alkyl. Non-limiting examples include methyl ammonium
(CH3)], dimethyl ammonium [HN+H(CH3)2], trimethyl ammonium H3)3],
ethyl ammonium [HN+H2(CH2CH3)], diethyl ammonium [HN+H(CH2CH3)2], triethyl
ammonium [HN+(CH2CH3)3], dimethylethyl ammonium H3)2(CH2CH3)], and
methyldiethyl ammonium H3)(CH2CH3)2].
Another iteration of this embodiment relates to cations wherein one or more of Ra,
Rb and Rc are chosen from hydrogen, unsubstituted C1—C12 linear, C3—C12 branched, or C3—
C12 cyclic alkyl or substituted C1—C12 linear, C3—C12 branched, or C3—C12 cyclic alkyl. One
embodiment relates to organic s haVing one or more C1-C12 linear, C3-C12 branched,
or C3—C12 cyclic alkyl chains substituted with hydroxy. Non-limiting examples include 2-
hydroxyethyl ammonium (cation of monoethanolamine, cholinate) [HN+H2(CH2CHZOH)],
methyl-2—hydroxyethyl um [H2N+(CH3)(CH2CHZOH)], di(2-hydroxyethyl)
ammonium [H2N+(CH2CHZOH)2], tri(2—hydroxyethyl) ammonium [HN+(CH2CHZOH)3],
and tris(hydroxymethyl)methyl ammonium (cation of tris(hydroxymethyl)aminomethane)
[H3N+C[(CHZOH)]3]. Also included are cations formed from amino sugars, for example,
amino sugars haVing the formula H2N+(CH3)[(CHOH)HCHZOH] wherein n is from 1 to 7. A
non-limiting example of an amino sugar suitable for g an organic cation is
meglumine (l-deoxy- l lamino-sorbitol).
A further iteration of this embodiment relates to cations formed from amino acids.
Non-limiting examples include lysine, omithine, arginine, glutamine, and the like.
Another aspect of organic amines suitable for forming salts of the sed
stabilizer include amines n one or more of Ra, Rb and R0 are taken together to form a
heterocyclic ring that can comprise from 3 to 20 atoms and optionally one or more
atoms chosen from nitrogen, oxygen and sulfur. Non-limiting examples e
piperazine, piperidine, line, thiomorpholine, and the like.
In addition, di-Valent cations can be used wherein the salts of these examples have
the formula:
\N o
121 A 9
OH O 2
Non-limiting examples of di-valent cations includes calcium magnesium, barium and the
like.
Another example of salts includes the di-anions having the formula:
O \
N 0
e l
09 2M / \L/u\09
O O
and 9 2
wherein M is the same as defined herein above.
The ance of the herein disclosed ediates lies in the fact that the
formulator can prepare an admixture comprising a plurality of final compounds in one step
by the choice of reactants in the final process step as described herein. For example, it is
known by the artisan that, although two or more analogs can have approximately equal
pharmacological ty, other properties such as bioavailability can be different. Using
the disclosed ediates to form admixtures of final analogs can provide the formulator
with a final composition which es the disparate pharmacological activities of the
les to e for a nt level of a desired property. For example, one analog in
the admixture can have immediate bioavailability while a second or third compound has a
slower bioavailability which can provide a pharmacologically active composition that has a
steady or near steady level of drug active in a user.
PROCESS
Disclosed herein is a process for preparing the herein above disclosed [(5—phenyl—3—
hydroxypyridinecarbonyl)-amino]alkanoic acids and [(5-heteroarylhydroxypyridine-
2-carbonyl)-amino]alkanoic acids. As disclosed herein, the 5-phenyl and 5-heteroaryl rings
can be substituted by one or more independently chosen substitutions for hydrogen.
The following is a summary of the steps that comprise the disclosed process.
Step A
Z R10
Y \
R10 B/ \
+ —>
\Y /
CN I
Al A2 A3
Step A relates to the condensation of an aryl or heteroaryl borate precursor, Al, and
a 3,5-dihalocyanopyridine, A2, n each Z is independently chloro or bromo, to
form a 5-aryl or 5-heteroarylhalocyanopyridine, A3.
The borate precursor, Al, comprises ring A wherein ring A can be:
A) substituted or unsubstituted C6 or C10 aryl; and
ii) substituted or tituted C1—C9 heteroaryl;
wherein the substitutes for hydrogen atoms on the A ring are one or more R10 units that are
independently chosen and further described herein. Y is ORZO, wherein R20 is hydrogen or
C1—C6 linear, C3—C6 branched, or C3-C6 cyclic alkyl, or two OR20 units can be taken together
to form a 5—member to 7—member C3-C10 cyclic ester, for e, a cyclic ester having the
formula:
C10 (on
1‘3’0 0 1'3’0
or .
One aspect of borate precursors relates to phenyl boronic acid having the formula:
0B/OH
Another aspect of borate precursors relates to tuted boronic acids having the
formula:
R10 |
\ 1'3/0H
wherein R10 represents from 1 to 5 substitutions as d herein above. Non-limiting
examples of this aspect includes borate precursors having the formula:
/©\ 0
OH E0 OH
c1 13’ 0 1'3’
(IDH and 0H
The 3,5-dihalocyanopyridine, A2, is chosen from 3,5-dichlorocyanopyridine,
3—chloro—5—bromo—2—cyanopyridine, 3,5—dibromo—2—cyanopyridine and 3—bromo—5—chloro—2—
cyanopyridine.
Step A is conducted in the presence of a catalyst, for example, a Suzuki coupling
catalyst. The formulator can choose the catalyst and conditions that are compatible with the
reagents, i.e., borate precursor and 3,5—dihalo—2—cyanopyridine. (See, Suzuki, A. Pure Appl.
Chem.1991, 63, 419—422; Suzuki, A., J. Organometallic Chem. 1999, 576, 147—168;
Barder, T. E. et al., “Catalysts for Suzuki—Miyaura Coupling Processes: Scope and Studies
of the Effect of Ligand Structure,” J. Am. Chem. Soc. 2005, 127, 4685—4696 included herein
by reference in their entirety.)
In one embodiment, the catalyst is [1,1’-bis(diphenyphosphino)ferrocene]dichloro—
ium(II) [PdClz(dppf)].
Another ry of catalysts include metalated catalysts with alkylphosphine
ligands of the general formula [Pd(X)(K2N,C—C6H4CH2NMe2)(PR3)] wherein R is Cy, X is
trifluoroacetate, trifluoromethanesufonyl, chloro, or iodo; PR3 is PCy2(0-biphenyl), X is
trifluoroacetate). Non-limiting examples of this category include [{Pd(u-TFA)(K2N,C-
2NMe2)}2] and [{Pd(TFA)(K2N,C—C6H4CH=NiPr)}2].
The catalyst can be preformed, for example, purchased from a al supplier or
the catalyst can be generated in situ. One non-limiting example of Step A n the
catalyst is generated in situ includes the following ure. Pd(OAc)2 (1.5 mmol %),
3 ,3 ’-dimethyl- l l ’(2,4-bismethylenemesitylene)(4,4,5,6-tetrahydropyrimidinium) chloride
(1.5 mmol %), a borate precursor (1.5 mmol), a 3,5-dihalocyanopyridine (1.0 mmol),
K2C03 (2 mmol), water (3 mL)-DMF (3 mL) are added to a small Schlenk tube and the
mixture heated at 80 0C for 5 hours. At the conclusion of the reaction, the mixture is
collected, removed by extraction with suitable solvent, and the desired product isolated by
methods known to the artisan.
Step A is conducted in the presence of a base. Non—limiting examples of suitable
bases that can be used in Step A includes LiOH, NaOH, KOH, Ca(OH)2, LizCO3, NazCO3,
K2CO3, and CaCO3. In one embodiment, the base is K2C03. In another embodiment, the
base is NazCO3.
Step A can be optionally ted in the presence of a solvent. miting
examples of solvents include water, formic acid, acetic acid; alcohols, for example,
methanol, ethanol, trichlorethanol, propanol, isopropanol, butanol, tert—butanol, and
the like; ketones, for example, acetone, methyl ethyl ketone, diethyl ketone, and the like;
esters, for example, methyl acetate, ethyl acetate, methyl propionate, ethyl propionate, and
the like; ethers, for e, l ether, methyl utyl ether, tetrahydrofuran,
dimethoxyethane, bis(2—methoxyethyl) ether (diglyme), l,4-dioxane,and the like; alkanes,
for example, e, isopentane, petroleum ether, hexane, mixtures of hexanes,
cyclohexane, 35eptanes, isoheptane, octane, isooctane, and the like; halogenated solvents,
for example, dichloromethane, chloroform, carbon hloride, l,l-dichloroethane, l,l,l-
trichloroethane, l,2-dichloroethane, chlorobenzene, and the like; aromatic hydrocarbons, for
example, e, toluene, l,2—dimethylbenzene (ortho-xylene), l,3-dimethylbenzene
(meta—xylene), l,4—dimetylbenzene (para-xylene), nitrobenzene, and the like; r
aprotic solvents, for example, acetonitrile, dimethylsulfoxide, N,N—dimethylformamide,
N,N—diethylformamide, N,N—dimethylacetamide, N,N—diethylacetamide, N—methyl-2—
pyrrolidinone, carbon disulfide, and hexamethylphosphoramide; and mixtures of one or
more solvents.
The reaction can be conducted at any ature sufficient to provide the desired
products or desired products.
Step B
A3 B
Step B relates to the conversion of a 5-aryl or 5-heteroarylhalocyanopyridine,
A3, to a 5-aryl or 5-heteroarylalkoxycyanopyridine, B.
Compound A3 is d with an alkoxide having the formula:
9 OR2
wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl. In one embodiment of step B,
intermediate A3 can be reacted with ide anion. The ide anion can be
generated in situ, for example, by the addition of an alkali metal to methanol. In one
example, from 1 lent to 10 equivalents of sodium metal based upon the amount of A3
to be converted in Step B, is added to an excess of methanol. In another example, an alkali
metal is added to an excess of methanol, the t removed, and the resulting sodium
methoxide retained for use when, for example, Step B is conducted in a solvent other than
methanol.
In another embodiment, the intermediate A3 can be reacted with ethoxide anion
generated from ethanol. In still r embodiment, the ediate A3 can be reacted
with isopropoxy anion generated from isopropanol.
As such, step B can be conducted at any temperature sufficient to provide the
desired ts or desired products. In on, step B can be conducted in any solvent or
mixtures of solvents that do not react with methoxide anion under the conditions chosen by
the formulator.
Step C
R10 R10
\N \N
/ / OH
0R2 OH 0
B C
Step C relates to the conversion of the 5—aryl or 5—heteroaryl—3—alkoxy—2—
cyanopyridine formed in step B to form a 5-aryl or 5-heteroarylhydroxy
carboxypyridine, C, (5-aryl or 5-heteroaryl-3 -hydroxypicolinic acid). This conversion can
be conducted in the presence of any acid capable of hydrolysis of the cyano moiety to a
carboxylic acid moiety and the methoxy moiety to a hydroxyl moiety. In one embodiment,
48% aqueous HBr can be used. In another embodiment, 37% aqueous HCl can be used.
The compounds having formula C can be isolated as the free acid or as a salt, for
e, as a compound having the formula:
as further described herein. Depending upon the intended use of the products of step C, the
formulator can proceed to step D or retain the ts of step C for use in preparing
admixtures of prolyl hydroxylase inhibitors or for preparing prodrugs of prolyl hydroxylase
inhibitors.
Step D
/ on R10
\N O
OH 0 118
+ N\(CR7aR7b))J\Xn
OH 0
1'18 0
H’N\(CR7aR7b)n/u\x
D1 D2
Step D relates to the reaction of the 5-aryl or 5-heteroaryl-3 -hydroxy
ypyridine formed in step C with a compound having formula D1, wherein X is
chosen from —OH, —OR3, —NR4R5 or —OM1 as defined herein above, to form one of the
following:
i) a prolyl hydroxylase inhibitor;
ii) a prolyl hydroxylase inhibitor prodrug;
iii) an admixture of prolyl hydroxylase inhibitors;
iv) an admixture of prolyl hydroxylase inhibitor prodrugs; or
V) le pharmaceutical salts thereof.
One aspect of step D relates to ion of a prolyl hydroxylase inhibitor according
to the ing scheme:
/ OH
\ 8
OH O N
I If
+ / CO H
\(CR7aR7b)n/ 2
If8 on o
/N CO H
H \(CR7aR7b)n/ 2
l5 D
wherein R73, R7b, R8 and the index n are defined herein above.
Another aspect of step D relate to formation of a prolyl hydroxylase ester prodrug
according to the following scheme:
2012/040833
/ OH
\ 8
OH 0 N
_> If
+ / N\(CR73R7b)/COZRn
I OH 0
N COZR3
H’ \(CR7aR7b)n/
wherein R3, R7a, R7b, R8 and the index n are defined herein above.
A further aspect of step D relate to formation of a prolyl hydroxylase amide prodrug
according to the following scheme:
/ OH
OH O \N
+ / If CONR4R5
\(CR7aR7b)n/
N OH O
CONR4R5
H’ \(CR7aR7b)n/
wherein R4, R5, R7a, R7b, R8 and the index n are defined herein above.
Step D relates to the coupling of a 5-aryl or roarylhydroxycarboxy-
pyridine, C, prepared in Step C with an amino acid, amino acid ester, or amino acid amide.
Any coupling reagent compatible with the 5-aryl or 5-heteroarylhydroxycarboxy-
pyridine, amino acid, amino acid ester, or amino acid amide can be used to prepare the
desired prolyl hydroxylase inhibitors or prodrugs thereof. Non-limiting examples of
coupling reagents includes carbonyldiimidazole (CD1), dicyclohexylcarbodiimide (DCC),
diisopropylcarbodiimide (DIC), and ethyl-(N’,N’-dimethylamino)propylcarbodiimide
(EDC), (benzotriazol-l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate
(BOP), (benzotriazol-l-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP),
zotriazol-l-yl)-N,N,N’N’-tertaetyluronium hexafluorophosphate (HBTU), O-
(benzotriazol-l-yl)-N,N,N’N’-tertamethyluronium tetrafluoroborate (TBTU), O-(7-
azabenzotriazol- l -yl)-N,N,N’N’-tetramethyluronium uorophosphate (HATU), O—(6—
chlorobenzotriazol-l-yl)-N,N,N’N’-tetramethyluronium hexafluorophosphate (HCTU), O-
(3 ,4-dihydrooxo- l ,2,3 -benzotriazine-3 -yl)-N,N,N’N’ -tetramethyluronium
uorophosphate ), and 3-(diethylphosphoryloxy)—l,2,3-benzotriazin-4(3H)-
one (DEPBT). In one iteration, wherein R8 is not hydrogen, step D can be ted With a
suitable reagent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
(PyBrOP).
A further iteration of the reaction outlined in step D es an in situ generated
mixed anhydride of the 5-aryl or 5-heteroarylhydroxy-2—carboxypyridine, for e,
reacting compound C with a mixed anhydride forming t. Non-limiting examples
include isobutylchloro-formate (IBCF), ethylchoroformate, isopropylchloroformate, and the
like. Other coupling reagents e 2-chloro-3,6-dimethoxy-1,3,5-triazine, pivalolyl
chloride and triphosgene. In another iteration, acyl chlorides can be used to activate the
carbonyl moiety of compound C for the coupling exemplified in step D.
In a yet further embodiment pivaloyl chloride in THF are used to catalyze the
coupling reaction.
An organic or inorganic base can be used for conducting step D. Non-limiting
examples of suitable organic bases include diisopropylethylamine, and the like.
Step D can be conducted in one or more solvents. Non—limiting examples of
ts include dimethylformamide (DMF), diethylformamide (DEF), dimethylacetamide
(DMA), diethylacetamide(DEA), dimethyl sulfoxide(DMSO), dioxane, and water. In one
embodiment, a mixture of water and one or more polar c solvents can be used, for
example, DMF/water, DMSO/water, dioxane/water, DMF/dioxane/water, and the like.
In some embodiments of the disclosed process, due to the type of substitution R10 on
ring A, the formulator can form a prodrug prior then further process the prodrug to the final
prolyl hydroxylase inhibitor. For example, the intermediate C may se an R10 unit
that has a protecting group present, i.e., carbobenzyloxy, tert—butoxycarbonyl, and the like.
In such examples it can be more convenient for the formulator to form the final product in
prodrug form, remove the protecting group then in a Step E, hydrolyze the g to the
free acid. The hydrolysis can be conducted in any suitable acid or base.
The ions of Step D can be modified by the formulator to meet the ties
of the reagents.
Scheme I herein below outlines and Example 1 describes a non-limiting example of
the sed process for the preparation of a prolyl hydroxylase ester pro-drug.
+ —> \
/ N
B/OH CN
I c1 CN
Reagents and conditions: (a) K2C03, PdC12(dppf), DMF; 45 0C, 18 hr.
Reagents and ions: (b) NaOCH3, CH3OH; reflux, 20 hr.
c] C1
/ /
OCH3 OH 0
2 3
Reagents and conditions: (c) 48% HBr; reflux, 20 hr.
c1 c1
\N + “Qt —» \N
I o
OCH3 wkH / 0H /
OCH3
OH 0 OH 0
3 4
Reagents and conditions: (d) CD1, DIPEA, DMSO; rt, 2.5 hr.
EXAMPLE 1
Methyl {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetate (4)
Preparation of 5-(3-chlorophenyl)-3 -chlorocyanopyridine (1): To a 100 mL
round bottom flask adapted for ic stirring and equipped with a nitrogen inlet was
charged (3 —chlorophenyl)boronic acid (5 g, 32 mmol), 3,5—dichloro—2—cyanopyridine (5.8 g,
34 mmol), K2C03 (5.5 g, 40 mmol), [1,1’—bis(diphenyphosphino)ferrocene]dichloro—
palladium(II) [PdClz(dppf)] (0.1 g, 0.13 mmol), dimethylformamide (50 mL) and water
(5mL). The reaction solution was agitated and heated to 45 0C and held at that temperature
for 18 hours after which the reaction was determined to be complete due to the
disappearance of 3,5—dichloro—2-cyanopyridine as measured by TLC analysis using ethyl
acetate/methanol (4: 1) as the mobile phase and UV 435 nm to visualize the reaction
components. The reaction solution was then cooled to room temperature and the contents
partitioned between ethyl acetate (250 mL) and saturated aqueous NaCl (100 mL). The
organic phase was isolated and washed a second time with saturated aqueous NaCl (100
mL). The organic phase was dried for 4 hours over MgSO4, the MgSO4 removed by
filtration and the solvent removed under reduced pressure. The residue that remained was
then slurried in methanol (50 mL) at room temperature for 20 hours. The resulting solid
was collected by ion and washed with cold methanol (50 mL) then s (60 mL)
and dried to afford 5.8 g (73% yield) of an admixture containing a 96:4 ratio of the desired
regioisomer. 1H NMR (DMSO—ds) 8 9.12 (d, 1H), 8.70 (d, 1H), 8.03 (t, 1H) 7.88 (m, 1H),
and 7.58 (m, 2H).
Preparation of 5-(3-chlorophenyl)-3 -methoxycyanopyridine (2): To a 500 mL
round bottom flask adapted for magnetic stirring and fitted with a reflux condenser and
nitrogen inlet was charged with hlorophenyl)-3 -chlorocyanopyridine, 1, (10 g, 40
mmol), sodium methoxide (13.8 mL, 60 mmol) and methanol (200 mL). With stirring, the
reaction on was heated to reflux for 20 hours. The reaction was ined to be
complete due to the earance of 5—(3 -chlorophenyl)—3—chloro—2—cyanopyridine as
measured by TLC analysis using hexane/ethyl e (6:3) as the mobile phase and UV 435
nm to visualize the reaction components. The on mixture was cooled to room
temperature and combined with water (500 mL). A solid began to form. The mixture was
cooled to 0 0C to 5 °C and stirred for 3 hours. The resulting solid was collected by filtration
and washed with water, then hexane. The resulting cake was dried in vacuo at 40 °C to
afford 9.4 g (96% yield) of the desired product as an off—white solid. 1H NMR (DMSO—d6)
8 8.68 (d, 1H), 8.05 (d, 1H), 8.01 (s, 1H) 7.86 (m, 1H), 7.59 (s, 1H), 7.57 (s, 1H) and 4.09
(s, 3H).
Preparation of 5-(3-chlorophenyl)hydroxypyridinecarboxylic acid (3): To a 50
mL round bottom flask adapted for magnetic stirring and fitted with a reflux condenser was
charged 5-(3 -chlorophenyl)-3 -methoxycyanopyridine, 2, (1 g, 4 mmol) and a 48%
aqueous solution of HBr (10 mL). While being stirred, the reaction solution was heated to
reflux for 20 hours. The reaction was determined to be complete due to the disappearance
of 5-(3-chlorophenyl)-3 -methoxycyanopyridine as measured by TLC analysis using
hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to Visualize the on
components. The reaction contents was then cooled to 0 0C to 5 0C with stirring and the pH
was adjusted to imately 2 by the slow addition of 50% aqueous NaOH. Stirring was
then continued at 0 °C to 5 0C for 3 hours. The resulting solid was collected by filtration
and washed with water, then . The resulting cake was dried in vacuo at 40 °C to
afford 1.03 g (quantitative yield) of the desired product as an off-white solid. 1H NMR
(DMSO—dg) 8 8.52 (d, 1H), 7.99 (d, 1H), 7.95 (s, 1H) 7.81 (t, 1H), 7.57 (s, 1H), and 7.55 (s,
1H).
Preparation of methyl {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetate
(4): To a 50 mL round bottom flask adapted for magnetic stirring and fitted with a en
inlet tube was charged 5-(3-chlorophenyl)hydroxypyridinecarboxylic acid, 3, (1 gm, 4
mmol), N,N’ nyldiimidazole (CD1) (0.97 g, 6 mmol) and dimethyl sulfoxide (5 mL).
The reaction mixture was stirred at 45 0C for about 1 hour then cooled to room temperature.
e methyl ester hydrochloride (1.15 g, 12 mmol) is added followed by the dropwise
addition of diisopropylethylamine (3.2 mL, 19 mmol). The mixture was then d for 2.5
hours at room ature after which water (70 mL) was added. The contents of the
reaction flask was cooled to 0 °C to 5 0C and 1N HCl was added until the solution pH is
approximately 2. The solution was extracted with dichloromethane (100 mL) and the
organic layer was dried over MgSO4 for 16 hours. Silica gel (3 g) is added and the solution
ed for 2 hours after which the solids are removed by filtration. The filtrate is
concentrated to dryness under reduced pressure and the resulting residue was slurried in
methanol (10 mL) for two hours. The resulting solid was collected by ion and washed
with cold methanol (20 mL) then hexane and the resulting cake is dried to afford 0.85 g of
the desired product as an off-white solid. The filtrate was treated to afford 0.026 g of the
desired product as a second crop. The combined crops afford 0.88 g (68% yield) of the
desired product. 1H NMR (DMSO—d6) 8 12.3 (s, 1H), 9.52 (t, 1H), 8.56 (d, 1H), 7.93 (s,
1H), 7.80 (q, 2H), 7.55 (t, 2H), 4.12 (d, 2H), and 3.69 (s, 3H).
The formulator can readily scale up the above disclosed synthesis. Disclosed herein
below is a synthesis wherein the sed process is scaled up for commercial use.
EXAMPLE 2
Methyl {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetate (4)
ation of 5-(3-chlorophenyl)-3 -chlorocyanopyridine (1): A 20 L reactor
equipped with a mechanical stirrer, dip tube, thermometer and nitrogen inlet was charged
with (3—chlorophenyl)boronic acid (550 g, 3.52 mol), chloro—2—cyanopyridine (639 g,
3.69 mol), K2CO3 (5.5 g, 40 mmol), [1,1’—bis(diphenyphosphino)ferrocene]dichloro—
palladium(H) (dppf)] (11.5 g, 140 mmol), and dimethylformamide (3894 g, 4.125 L).
The reaction solution was agitated and purged with nitrogen h the dip-tube for 30
minutes. Degassed water (413 g) was then charged to the reaction e while
maintaining a temperature of less than 50 °C 25 hours. The reaction was determined to be
complete due to the earance of 3,5—dichloro—2—cyanopyridine as measured by TLC
analysis using ethyl acetate/methanol (4: 1) as the mobile phase and UV 435 nm to visualize
the reaction components. The reaction solution was then cooled to 5 0C and charged with
heptane (940 g, 1.375 L) and agitated for 30 minutes. Water (5.5 L) was charged and the
e was further agitated for 1 hour as the temperature was allowed to rise to 15 0C. The
solid product was isolated by filtration and washed with water (5.5 L) followed by heptane
(18881 g, 2750 ML). The resulting cake was air dried under vacuum for 18 hours and then
triturated with a mixture of 2-propanol (6908 g, 8800 mL0 and heptane (1 g, 2200mL0 at 50
0C for 4 hours, cooled to ambient ature and then agitated at ambient temperature for
1 hour. The product was then isolated by filtration and washed with cold 2-propanol (3450
g, 4395 mL) followed by heptane (3010 g, 4400mL). The resulting solid was dried under
high vacuum at 40 °C for 64 hours to afford 565.9 g (65% yield) of the desired product as a
beige solid. Purity by HPLC was 98.3. 1H NMR (DMSO—d6) 8 9.12 (d, 1H), 8.70 (d, 1H),
8.03 (t, 1H) 7.88 (m, 1H), and 7.58 (m, 2H).
Preparation of 5-(3-chlorophenyl)methoxycyanopyridine (2): A 20 L reactor
equipped with a mechanical stirred, condenser, meter and nitrogen inlet was charged
with 5-(3 -chlorophenyl)chlorocyanopyridine, 1, (558 g, 2.24 mol) and sodium
methoxide (25% solution in methanol, 726.0 g, 3.36 mol). With agitation, the on
solution was heated to reflux for 24 hours, resulting in a beige—colored suspension. The
reaction was determined to be complete due to the disappearance of 5—(3 —chlorophenyl)—3—
chlorocyanopyridine as measured by TLC analysis using hexane/ethyl acetate (6:3) as
the mobile phase and UV 435 nm to Visualize the reaction components. The reaction
mixture was cooled to 5 0C and then charged with water (5580 mL). The resulting slurry
was agitated for 3 hours at 5 0C. The solid product was ed by filtration and washed
with water (5580 mL) until the filtrate had a pH of 7. The filter cake was air dried under
vacuum for 16 hours. The filter cake was then charged back to the reactor and triturated in
MeOH (2210 g, 2794 mL) for 1 hour at ambient temperature. The solid was collected by
filtration and washed with MeOH (882 g, 1116 mL, 5 0C) followed by heptane (205 mL,
300mL), and dried under high vacuum at 45 0C for 72 hours to afford 448 g (82% yield) of
the desired product as an ite solid. Purity by HPLC was 97.9%. 1H NMR (DMSO—
d6) 8 8.68 (d, 1H), 8.05 (d, 1H), 8.01 (s, 1H) 7.86 (m, 1H), 7.59 (s, 1H), 7.57 (s, 1H) and
4.09 (s, 3H).
Preparation of 5-(3-chlorophenyl)-3 -hydroxypyridinecarboxylic acid (3): A 20 L
reactor equipped with a mechanical stirrer, condenser, thermometer, nitrogen inlet and 25%
aqueous NaOH trap was charged 5—(3 —chlorophenyl)methoxycyanopyridine, 2, (440.6
g, 1.8 mol) and 37% aqueous solution of HCl (5302 g). While being agitated, the reaction
solution was heated to 102 0C for 24 hours. Additional 37% aqueous HCl (2653 g) was
added followed by agitation for 18 hours at 104 0C. The on contents was then cooled
to 5 0C, d with water (4410 g) and then agitated at 0 0C for 16 hours. The resulting
itated t was isolated by filtration and washed with water until the filtrate had a
pH of 6 (about 8,000 L of water). The filter cake was pulled dry under reduced pressure for
2 hours. The cake was then transferred back into the reactor and triturated in THF (1958 g,
2201 mL) at ambient temperature for 2 hours. The solid product was then isolated by
filtration and washed with THF (778 g, 875 mL) and dried under reduced re at 5 °C
for 48 hours to afford 385 g (89% yield) of the desired product as an off—white solid. HPLC
purity was 96.2%. 1H NMR (DMSO—d6) 8 8.52 (d, 1H), 7.99 (d, 1H), 7.95 (s, 1H) 7.81 (t,
1H), 7.57 (s, 1H), and 7.55 (s, 1H).
Preparation of methyl {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetate
(4): A 20 L reactor equipped with a mechanical r, condenser, thermometer and
nitrogen inlet was charged with 5-(3 -chlorophenyl)-3 -hydroxypyridinecarboxylic acid, 3,
(380 g, 1.52 mol) and diisopropylethylamine )(295 g, 2.28 mol). With agitation, the
solution was cooled to 3 0C and charged with trimethylacetyl chloride (275.7 g, 2.29 mol)
while maintaining a temperature of less than 11 0C, The mixture was then agitated at
ambient temperature for 2 hours. The e was then cooled to 10 0C and charged with a
slurry of glycine methyl ester HCl (573.3 g, 4. 57 mol) and THF (1689 g, 1900mL), then
charged with DIPEA (590.2 g, 4.57 mol) and agitated at ambient temperature for 16 hours.
The mixture was then charged with EtOH (1500 g, 1900 mL) and concentrated under
d pressure to a reaction volume of about 5.8 L. The EtOH addition and concentration
was repeated twice more. Water (3 800g) was then added and the mixture was agitated for
16 hours at ambient temperature. The resulting solid product was isolated by filtration and
washed with a mixture of EtOH (300g, 380 mL) and water (3 80 g), followed by water
(3 800g), dried under reduced pressure for 18 hours at 50 °C to afforded 443 g (91% yield)
of the desired product as an off—white solid. Purity by HPLC was 98.9%. 1H NMR (DMSO—
d6) 8 12.3 (s, 1H), 9.52 (t, 1H), 8.56 (d, 1H), 7.93 (s, 1H), 7.80 (q, 2H), 7.55 (t, 2H), 4.12 (d,
2H), and 3.69 (s, 3H).
Scheme 11 herein below outlines and Example 2 describes a non-limiting example of
the disclosed process for ing a prolyl hydroxylase inhibitor from an ester prodrug.
Scheme 11
C1 C1
N —> \
o N o
H H
/ NA / NA
OCH3 OH
OH O OH O
4 5
Reagents and conditions: (a) NaOH, THF; 2 hr.
{[5-(3 -Chlorophenyl)hydroxypyridinyl]amino}acetic acid (5)
ation of {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetic acid (5):
To a 50 mL flask is charged methyl {[5-(3-chlorophenyl)hydroxypyridinyl]amino}-
acetate, 4, (0.45 g, 1.4 mmol), tetrahydrofuran (4.5 mL) and 1 M NaOH (4.5 mL, 4.5
mmol). The mixture was stirred for 2 hours at room temperature after which it was
determined by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV
435 nm to Visualize the reaction ents that the reaction was complete. The reaction
on was adjusted to pH 1 with concentrated HCl and the solution was heated at 35 0C
under vacuum until all of the tetrahydrofuran had been removed. A slurry forms as the
solution is trated. With efficient stirring the pH is adjusted to ~2 with the slow
addition of 1 M NaOH. The solid which forms was collected by filtration, washed with
water, followed by hexane, then dried under vacuum to afford 0.38 g (88% yield) of the
desired t as a white solid. 1H NMR (DMSO—d6) 8 12.84 (s, 1H), 12.39 (s, 1H), 9.39
(t, 1H), 8.56 (d, 1H), 7.94 (s, 1H), 7.81 (m, 2H), 7.55 (q, 2H), and 4.02 (d, 2H).
The ator can readily scale up the above disclosed synthesis. Disclosed herein
below is a synthesis wherein the disclosed process is scaled up for commercial use.
{[5-(3 -Chlorophenyl)hydroxypyridinyl]amino}acetic acid (5)
Preparation of {[5-(3 -chlorophenyl)hydroxypyridinyl]amino}acetic acid (5):
To a 20 L reactor equipped with a mechanical stirrer, condenser, meter and nitrogen
inlet was charged methyl {[5-(3 -chlorophenyl)-3 -hydroxypyridinyl]amino}-acetate, 4,
(440 g, 1.42 mol), tetrahydrofuran (3912 g, 4400 mL) and 1 M NaOH (4400 mL). The
mixture was stirred for 2 hours at room temperature after which it was determined by TLC
analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize
the reaction components that the on was complete. The reaction solution was acidified
to a pH of 2 with slow addition of 2M HCl (2359 g). The resulting mixture was
concentrated under reduced pressure to a volume of about 7.5 L. Ware (2210 g) was added
and the solution cooled to ambient temperature and agitated for 18 hours. The solid product
was isolated by filtration and washed with water (6 L). the crude product was transferred
back into the reactor and triturated with 2215 g o deionized water at 70 0C for 16 hours.
The mixture was cooled to ambient temperature, The solid product was ed by
filtration and washed with water (500 mL) and dried under d pressure at 70 °C for 20
hours to afford 368 g (87% yield) of the desired product as an off—white solid. Purity by
HPLC was 99.3%. 1H NMR (DMSO—dg) 8 12.84 (s, 1H), 12.39 (s, 1H), 9.39 (t, 1H), 8.56
(d, 1H), 7.94 (s, 1H), 7.81 (m, 2H), 7.55 (q, 2H), and 4.02 (d, 2H).
Scheme III herein below outlines and Example 3 describes a non-limiting example
of the disclosed s for preparing a prolyl hydroxylase amide prodrug.
Scheme III
ts and conditions: (a) EDCI, HOBt, DIPEA, DMF; rt.
EXAMPLE 5
—(3—Chlorophenyl)-N—(2-aminooxoethyl)hydroxylpyridinyl amide
Preparation of hlorophenyl)-N—(2-aminooxoethyl)hydroxylpyridinyl
amide (6): To a solution of 5-(3-chlorophenyl)hydroxypyridinecarboxylic acid, 3,
(749 mg, 3 mmol) in DMF (20 mL) at room temperature under N2 is added 1-(3—dimethyl—
aminopropyl)—3—ethylcarbodiimide (EDCI) (0.925 g, 5.97 mmol) and 1—hydroxybenzo—
triazole (HOBt) (0.806 g, 5.97 mmol). The resulting solution is stirred for 15 s then
2-aminoacetamide hydrochloride (0.66 g, 5.97 mmol) and diisopropylethylamine (1.56 ml,
8.96 mmol) are added. The reaction is monitored by TLC and when the reaction is
complete the reaction mixture is trated under reduced pressure and H20 added. The
product can be isolated by normal work—up: The following data have been reported for
compound (6). 1H NMR (250 MHz, DMSO—d6) 8 ppm 12.46 (1 H, s), 9.17 (1 H, t, J= 5.9
Hz), 8.55 (1 H, d, J= 2.0 Hz), 7.93 (1 H, d, J= 0.9 Hz), 7.75 — 7.84 (2 H, m), 7.49 — 7.60 (3
H, m), 7.18 (1 H, s), 3.91 (2 H, d, J= 5.9 Hz). HPLC—MS: m/z 306 [M+H]+.
Scheme IV herein below depicts a non-limiting example the hydrolysis of an amide
pro-drug to a prolyl hydroxylase inhibitor after removal of a R10 protecting group.
Scheme IV
9\ j]: NH2
0 NH
—’ \
N o
{I} NH2
/ \Jk OH O
OH O
NH2 NH2
H H
/ NdL / NA
NH2 OH
OH O OH 0
While particular embodiments of the present sure have been rated and
described, it would be obvious to those skilled in the art that various other changes and
modifications can be made without departing from the spirit and scope of the disclosure. It
is therefore intended to cover in the appended claims all such changes and modifications
that are within the scope of this disclosure.
Claims (27)
1. A s for preparing a compound having the formula: wherein R1 is chosen from: i) substituted or unsubstituted C6 or C10 aryl; or ii) substituted or unsubstituted C1-C9 heteroaryl; L is a linking unit having the formula: –(CR7aR7b)n– R7a and R7b are each independently: i) hydrogen; or ii) C1-C6 linear, C3-C6 ed or C3-C6 cyclic alkyl; R8 is chosen from hydrogen, , or ethyl; and the index n is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof, comprising: A) reacting a boronic acid or ester having the formula: wherein Y is OR20, R20 is hydrogen or C1-C6 linear, C3-C6 branched, or C3- C6 cyclic alkyl, or two OR20 units can be taken together to form a 5-member to 7-member C3-C10 cyclic ester, with a 3,5-dihalocyanopyridine having the formula: each Z is ndently chloro or bromo, in the presence of a catalyst, to form a 5-aryl or 5-heteroarylhalocyanopyridine having the formula: B) reacting the 5-aryl or 5-heteroarylhalocyanopyridine formed in step (A) with an alkoxide anion having the formula: wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-aryl or 5-heteroarylalkoxycyanopyridine having the formula: C) reacting the 5-aryl or 5-heteroarylalkoxycyanopyridine formed in step (B) with an acid to form a 5-aryl or 5-heteroarylhydroxy carboxypyridine having the formula: ; and D) reacting the 5-aryl or roarylhydroxycarboxypyridine formed in step (C) with an amino acid having the formula:
2. The process according to Claim 1, wherein the boronic acid in step (A) is a substituted or unsubstituted phenyl boronic acid.
3. The process according to either Claim 1 or 2, wherein the boronic acid in step (A) is a phenyl boronic acid substituted with one or more units independently chosen from: i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and l; ii) C6 or C10 aryl; iii) C7 or C11 alkylenearyl; iv) C1-C9 cyclic rings; v) C1-C9 heteroaryl rings; vi) –(CR102aR102b)aOR101; vii) –(CR102aR102b)aC(O)R101; viii) –(CR102aR102b)aC(O)OR101; ix) –(CR102aR102b)aC(O)N(R101)2; x) –(CR102aR102b)aN(R101) C(O)R101; xi) 2aR102b)aN(R101) 101; xii) –(CR102aR102b)aN(R101)2; xiii) halogen; xiv) –(CR102aR102b)I; xv) –(CR102aR102b)aNO2; xvi) –(CHj’Xk’)aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j’ is an integer from 0 to 2, j’ + k’ = 2; xvii) –(CR102aR102b)aSR101; xviii) –(CR102aR102b)aSO2R101; and xix) –(CR102aR102b)aSO3R101; wherein each R101 is ndently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 ed alkyl; the index “a” is from 0 to 4
4. The process according to any one of Claims 1 to 3, wherein the boronic acid in step (A) is substituted by one or more units ndently chosen from: i) C1-C12 linear, C3-C12 ed or C3-C12 cyclic alkyl; ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or iii) halogen.
5. The process according to any one of Claims 1 to 4, wherein the boronic acid in step (A) is chosen from 2-fluorophenylboronic acid, 3-fluorophenylboronic acid, 4- fluorophenylboronic acid, 2-chlorophenylboronic acid, 3-chlorophenylboronic acid, 4-chlorophenylboronic acid, 2-methylphenylboronic acid, 3-methylphenylboronic acid, 4-methylphenylboronic acid, 2-methoxyphenylboronic acid, 3-methoxyphenylboronic acid, 4-methoxyphenylboronic acid, 2-cyanophenylboronic acid, 3-cyanophenylboronic acid, 4-cyanophenylboronic acid, 2-nitrophenylboronic acid, 3-nitrophenylboronic acid, ophenylboronic acid, 2-trifluoromethylphenylboronic acid, 3-trifluoromethylphenylboronic acid, 4-trifluoromethylphenylboronic acid, 2- carbamoylphenylboronic acid, 3-carbamoylphenylboronic acid, 4-carbamoylphenylboronic acid, 2-(pyrrolidinecarbonyl)phenylboronic acid, rolidine yl)phenylboronic acid, 4-(pyrrolidinecarbonyl)phenylboronic acid, 2-(cyclopropanecarbonylamino)phenylboronic acid, 3-(cyclopropanecarbonylamino )phenylboronic acid, and 4-(cyclopropanecarbonylamino)phenylboronic acid.
6. The process according to any one of Claims 1 to 5, wherein the catalyst in step (A) is [1,1’-bis(diphenyphosphino)ferrocene]dichloro-palladium(II).
7. The process according to any one of Claims 1 to 6, wherein the alkoxide in step (B) is methoxide.
8. The process according to any one of Claims 1 to 7, n the amino acid of step (D) is chosen from glycine, alanine, isoleucine, leucine, valine, 2-aminomethylpropanoic acid, 3-aminobutanoic acid, 3-aminomethylbutanoic acid, 3-amino methylbutanoic acid, and 4-aminobutanoic acid.
9. A process for ing a compound having the formula: n A is a ring chosen from: i) substituted or unsubstituted C6 or C10 aryl; or ii) substituted or unsubstituted C1-C9 heteroaryl; R10 represents one or more independently chosen optionally present substitutions for hydrogen; X is chosen from: i) –OH; ii) –OR3; iii) –NR4R5; and iv) –OM1; R3 is C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl, or benzyl; R4 and R5 are each independently hydrogen, C1-C12 linear, C3-C12 branched or C3- C12 cyclic alkyl; C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkenyl; or C2-C12 linear, C3-C12 branched or C3-C12 cyclic alkynyl; benzyl; or R4 and R5 can be taken er with the nitrogen atom to form a 3 to 10 member ring, wherein the ring can optionally contain one or more heteroatoms chosen from oxygen (O), nitrogen (N), or sulfur (S); M1 is a pharmaceutically acceptable cation; R7a and R7b are each ndently: i) hydrogen; or ii) C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; R8 is chosen from hydrogen, methyl, or ethyl; and the index n is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof, sing: A) reacting a boronic acid or ester having the formula: wherein Y is OR20, R20 is hydrogen or C1-C6 , C3-C6 branched, or C3- C6 cyclic alkyl, or two OR20 units can be taken together to form a 5-member to 7-member C3-C10 cyclic ester, with a 3,5-dihalocyanopyridine having the formula: each Z is independently chloro or bromo, in the presence of a st, to form a 5-aryl or 5-heteroarylhalocyanopyridine having the formula: B) reacting the 5-aryl or 5-heteroarylhalocyanopyridine formed in step (A) with an alkoxide anion having the a: wherein R2 is C1-C12 linear alkyl or C3-C12 branched alkyl, to form a 5-aryl or 5-heteroarylalkoxycyanopyridine having the formula: C) reacting the 5-aryl or 5-heteroarylalkoxycyanopyridine formed in step (B) with an acid to form a 5-aryl or 5-heteroarylhydroxy carboxypyridine having the formula: ; and D) reacting the 5-aryl or 5-heteroarylhydroxycarboxypyridine formed in step (C) with a compound having the a:
10. The process according to Claim 9, wherein the boronic acid in step (A) is a substituted or unsubstituted phenyl boronic acid.
11. The process according to either Claim 9 or 10, wherein the c acid in step (A) is a phenyl boronic acid wherein R10 represents one or more substitutions for en independently chosen from: i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, alkenyl, and alkynyl; ii) C6 or C10 aryl; iii) C7 or C11 alkylenearyl; iv) C1-C9 heterocyclic rings; v) C1-C9 heteroaryl rings; vi) –(CR102aR102b)aOR101; vii) –(CR102aR102b)aC(O)R101; viii) –(CR102aR102b)aC(O)OR101; ix) –(CR102aR102b)aC(O)N(R101)2; x) –(CR102aR102b)aN(R101) C(O)R101; xi) –(CR102aR102b)aN(R101) C(O)2R101; xii) –(CR102aR102b)aN(R101)2; xiii) halogen; xiv) –(CR102aR102b)I; xv) –(CR102aR102b)aNO2; xvi) Xk’)aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j’ is an integer from 0 to 2, j’ + k’ = 2; xvii) –(CR102aR102b)aSR101; xviii) –(CR102aR102b)aSO2R101; and xix) –(CR102aR102b)aSO3R101; wherein each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken er to form a ring comprising 3-7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3- C4 branched alkyl; the index “a” is from 0 to 4.
12. The process ing to any one of Claims 9 to 11, wherein R10 is one or more units independently chosen from: i) C1-C12 , C3-C12 branched or C3-C12 cyclic alkyl; ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or iii) n.
13. The process according to any one of Claims 9 to 12, wherein the c acid in step (A) is chosen from 2-fluorophenylboronic acid, 3-fluorophenylboronic acid, 4- fluorophenylboronic acid, 2-chlorophenylboronic acid, 3-chlorophenylboronic acid, 4-chlorophenylboronic acid, 2-methylphenylboronic acid, 3-methylphenylboronic acid, 4-methylphenylboronic acid, 2-methoxyphenylboronic acid, 3-methoxyphenylboronic acid, 4-methoxyphenylboronic acid, 2-cyanophenylboronic acid, 3-cyanophenylboronic acid, 4-cyanophenylboronic acid, 2-nitrophenylboronic acid, 3-nitrophenylboronic acid, 4-nitrophenylboronic acid, 2-trifluoromethylphenylboronic acid, 3-trifluoromethylphenylboronic acid, 4-trifluoromethylphenylboronic acid, 2- carbamoylphenylboronic acid, 3-carbamoylphenylboronic acid, 4-carbamoylphenylboronic acid, 2-(pyrrolidinecarbonyl)phenylboronic acid, 3-(pyrrolidine carbonyl)phenylboronic acid, rolidinecarbonyl)phenylboronic acid, 2-(cyclopropanecarbonylamino)phenylboronic acid, 3-(cyclopropanecarbonylamino )phenylboronic acid, and 4-(cyclopropanecarbonylamino)phenylboronic acid.
14. The process according to any one of Claims 9 to 13, n the catalyst in step (A) is [1,1’-bis(diphenyphosphino)ferrocene]dichloro-palladium(II).
15. The process according to any one of Claims 9 to 14, wherein the compound of step (D) is chosen from glycine, alanine, isoleucine, leucine, , 2-aminomethylpropanoic acid, obutanoic acid, 3-aminomethylbutanoic acid, 3-amino methylbutanoic acid, and 4-aminobutanoic acid.
16. The process ing to any one of Claims 9 to 14, wherein X is –OR3 or –NR4R5 further comprising the step of hydrolyzing the compound formed in step (D) to form a compound wherein X is –OH.
17. The process according to Claim 16, wherein the hydrolysis is conducted in the presence of an acid catalyst.
18. The process according to Claim 16, wherein the hydrolysis is conducted in the presence of a base catalyst.
19. A nd having the formula: wherein M is a salt forming cation and N represents the cationic charge on M; A is C10 aryl; R10 units represent at least one optionally present substitutions for a ring hydrogen atom; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted C6 or C10 aryl ring, a substituted or unsubstituted C2-C8 heterocyclic ring, or a tuted or unsubstituted C3 to C5 aryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S). L is a linking unit having the formula: –(CR7aR7b)n– R7a and R7b are each independently: i) hydrogen; or ii) C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; and the index n is an integer from 1 to 4.
20. The compound according to Claim 19, wherein A is tuted by one or more R10 units ndently chosen from: i) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic alkyl, l, and alkynyl; ii) C6 or C10 aryl; iii) C7 or C11 alkylenearyl; iv) C1-C9 heterocyclic rings; v) C1-C9 heteroaryl rings; vi) –(CR102aR102b)aOR101; vii) –(CR102aR102b)aC(O)R101; viii) –(CR102aR102b)aC(O)OR101; ix) –(CR102aR102b)aC(O)N(R101)2; x) –(CR102aR102b)aN(R101) C(O)R101; xi) –(CR102aR102b)aN(R101) C(O)2R101; xii) –(CR102aR102b)aN(R101)2; xiii) halogen; xiv) –(CR102aR102b)I; xv) –(CR102aR102b)aNO2; xvi) –(CHj’Xk’)aCHjXk; wherein X is halogen, the index j is an integer from 0 to 2, j + k = 3; the index j’ is an integer from 0 to 2, j’ + k’ = 2; xvii) –(CR102aR102b)aSR101; xviii) –(CR102aR102b)aSO2R101; and xix) –(CR102aR102b)aSO3R101; n each R101 is independently hydrogen, substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, phenyl, benzyl, heterocyclic, or heteroaryl; or two R101 units can be taken together to form a ring comprising 3-7 atoms; R102a and R102b are each independently hydrogen or C1-C4 linear or C3-C4 ed alkyl; the index “a” is from 0 to 4.
21. The compound according Claim 19 or 20, wherein A is substituted by one or more R10 units independently chosen from: i) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkyl; ii) C1-C12 linear, C3-C12 branched or C3-C12 cyclic alkoxy; or iii) halogen.
22. The compound according to Claim 19, wherein two R10 units are be taken together to form a substituted or unsubstituted C2-C8 cyclic ring, wherein the heterocyclic ring comprises one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S).
23. A compound or a pharmaceutically acceptable salt thereof, prepared by the process of any one of claims 1 to 18.
24. A process according to claim 1, substantially as herein described or exemplified.
25. A process according to claim 9, substantially as herein described or exemplified.
26. A compound ing to claim 19, ntially as herein described or exemplified.
27. A compound or a ceutically acceptable salt thereof according to claim 23, substantially as herein described or exemplified.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493536P | 2011-06-06 | 2011-06-06 | |
US61/493,536 | 2011-06-06 | ||
PCT/US2012/040833 WO2012170377A1 (en) | 2011-06-06 | 2012-06-05 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618570A NZ618570A (en) | 2015-07-31 |
NZ618570B2 true NZ618570B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7039682B2 (en) | [(5- (Halophenyl) -3-hydroxypyridin-2-carbonyl) -amino] 5-((Halophenyl) -3-halo-pyridin-2-yl) -nitrile derivative as an intermediate in the preparation of alkanoic acid derivatives | |
NZ618570B2 (en) | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides |